Axon Enterprise (AXON) 10-Q 6 Aug 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Jul. 30, 2021
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-16391
Entity Registrant Name	Axon Enterprise, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-0741227
Entity Address, Address Line One	17800 North 85th Street
Entity Address, City or Town	Scottsdale
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85255
City Area Code	480
Local Phone Number	991-0797
Title of 12(b) Security	Common Stock, $0.00001 Par Value
Trading Symbol	AXON
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		65,675,685
Entity Central Index Key	0001069183
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 266,372	$ 155,440
Short-term investments	388,895	406,525
Accounts and notes receivable, net of allowance of $1,973 and $2,105 as of June 30, 2021 and December 31, 2020, respectively	201,907	229,201
Contract assets, net	86,561	63,945
Inventory	91,739	89,958
Prepaid expenses and other current assets	45,456	36,883
Total current assets	1,080,930	981,952
Property and equipment, net	119,933	105,494
Deferred tax assets, net	52,387	45,770
Intangible assets, net	7,870	9,448
Goodwill	25,178	25,205
Long-term investments	48,669	90,681
Long-term notes receivable, net of current portion	17,466	22,457
Long-term contract assets, net	31,691	20,099
Strategic investments	58,520	11,711
Other assets	84,244	68,206
Total assets	1,526,888	1,381,023
Current liabilities:
Accounts payable	7,778	24,142
Accrued liabilities	66,908	59,843
Contract with customer, liability, current	186,909	163,959
Other current liabilities	6,404	5,431
Total current liabilities	272,871	256,331
Deferred revenue, net of current portion	113,815	111,222
Liability for unrecognized tax benefits	4,550	4,503
Long-term deferred compensation	5,216	4,732
Deferred tax liability, net	377	649
Other long-term liabilities	32,360	27,331
Total liabilities	429,189	404,768
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.00001 par value; 25,000,000 shares authorized; no shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively
Common stock, $0.00001 par value; 200,000,000 shares authorized; 65,674,346 and 63,766,555 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	1	1
Additional paid-in capital	1,179,005	962,159
Treasury stock at cost, 20,220,227 shares as of June 30, 2021 and December 31, 2020	(155,947)	(155,947)
Retained earnings	74,867	169,901
Accumulated other comprehensive income (loss)	(227)	141
Total stockholders' equity	1,097,699	976,255
Total liabilities and stockholders' equity	1,526,888	1,381,023
Current portion of deferred revenue
Current liabilities:
Contract with customer, liability, current	186,909	163,959
Customer deposits
Current liabilities:
Contract with customer, liability, current	$ 4,872	$ 2,956

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance on accounts receivable	$ 1,973	$ 2,105
Preferred stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	65,674,346	63,766,555
Common stock, shares outstanding (in shares)	65,674,346	63,766,555
Treasury stock, shares (in shares)	20,220,227	20,220,227

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net sales	$ 218,795	$ 141,259	$ 413,814	$ 288,421
Cost of sales	80,866	53,082	152,532	111,636
Gross margin	137,929	88,177	261,282	176,785
Sales, general and administrative	177,662	72,293	304,259	135,320
Research and development	53,952	29,560	100,970	55,941
Total operating expenses	231,614	101,853	405,229	191,261
Loss from operations	(93,685)	(13,676)	(143,947)	(14,476)
Interest and other income, net	41,841	1,613	42,426	2,554
Loss before provision for income taxes	(51,844)	(12,063)	(101,521)	(11,922)
Provision for (benefit from) income taxes	(4,727)	18,696	(6,487)	14,763
Net loss	$ (47,117)	$ (30,759)	$ (95,034)	$ (26,685)
Net loss per common and common equivalent shares:
Basic (in dollars per share)	$ (0.72)	$ (0.51)	$ (1.47)	$ (0.44)
Diluted (in dollars per share)	$ (0.72)	$ (0.51)	$ (1.47)	$ (0.44)
Weighted average number of common and common equivalent shares outstanding:
Basic (in shares)	65,166	60,346	64,604	59,977
Diluted (in shares)	65,166	60,346	64,604	59,977
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Net (loss) income	$ (47,117)	$ (30,759)	$ (95,034)	$ (26,685)
Foreign currency translation adjustments	(369)	678	(368)	(1,694)
Comprehensive loss	(47,486)	(30,081)	(95,402)	(28,379)
Product
Net sales	156,427	98,755	297,313	206,043
Cost of sales	65,301	43,825	123,917	92,709
Service
Net sales	62,368	42,504	116,501	82,378
Cost of sales	$ 15,565	$ 9,257	$ 28,615	$ 18,927

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Cumulative Effect Period Of Adoption Adjusted BalanceRetained Earnings	Cumulative Effect Period Of Adoption Adjusted Balance	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total
Beginning balance (in shares) at Dec. 31, 2019			59,497,759		20,220,227
Beginning balance at Dec. 31, 2019	$ (640)	$ (640)	$ 1	$ 528,272	$ (155,947)	$ 172,265	$ (1,096)	$ 543,495
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under employee plans, net (in shares)			315,404
Issuance of common stock under employee plans, net				(5,162)				(5,162)
Stock-based compensation				20,195				20,195
Net (loss) income						4,074		4,074
Foreign currency translation adjustments							(2,372)	(2,372)
Ending balance (in shares) at Mar. 31, 2020			59,813,163		20,220,227
Ending balance at Mar. 31, 2020			$ 1	543,305	$ (155,947)	175,699	(3,468)	559,590
Beginning balance (in shares) at Dec. 31, 2019			59,497,759		20,220,227
Beginning balance at Dec. 31, 2019	$ (640)	$ (640)	$ 1	528,272	$ (155,947)	172,265	(1,096)	543,495
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income								(26,685)
Foreign currency translation adjustments								(1,694)
Ending balance (in shares) at Jun. 30, 2020			63,468,347		20,220,227
Ending balance at Jun. 30, 2020			$ 1	883,609	$ (155,947)	144,940	(2,790)	869,813
Beginning balance (in shares) at Mar. 31, 2020			59,813,163		20,220,227
Beginning balance at Mar. 31, 2020			$ 1	543,305	$ (155,947)	175,699	(3,468)	559,590
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)			3,450,000
Issuance of common stock				306,779				306,779
Issuance of common stock under employee plans, net (in shares)			134,571
Issuance of common stock under employee plans, net				(310)				(310)
Stock-based compensation				33,835				33,835
Issuance of common stock for business combination contingent consideration (in shares)			70,613
Net (loss) income						(30,759)		(30,759)
Foreign currency translation adjustments							678	678
Ending balance (in shares) at Jun. 30, 2020			63,468,347		20,220,227
Ending balance at Jun. 30, 2020			$ 1	883,609	$ (155,947)	144,940	(2,790)	869,813
Beginning balance (in shares) at Dec. 31, 2020			63,766,555		20,220,227
Beginning balance at Dec. 31, 2020			$ 1	962,159	$ (155,947)	169,901	141	976,255
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under employee plans, net (in shares)			906,536
Issuance of common stock under employee plans, net				(7,045)				(7,045)
Stock-based compensation				89,610				89,610
Net (loss) income						(47,917)		(47,917)
Foreign currency translation adjustments							1	1
Ending balance (in shares) at Mar. 31, 2021			64,673,091		20,220,227
Ending balance at Mar. 31, 2021			$ 1	1,044,724	$ (155,947)	121,984	142	1,010,904
Beginning balance (in shares) at Dec. 31, 2020			63,766,555		20,220,227
Beginning balance at Dec. 31, 2020			$ 1	962,159	$ (155,947)	169,901	141	976,255
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income								(95,034)
Foreign currency translation adjustments								(368)
Ending balance (in shares) at Jun. 30, 2021			65,674,346		20,220,227
Ending balance at Jun. 30, 2021			$ 1	1,179,005	$ (155,947)	74,867	(227)	1,097,699
Beginning balance (in shares) at Mar. 31, 2021			64,673,091		20,220,227
Beginning balance at Mar. 31, 2021			$ 1	1,044,724	$ (155,947)	121,984	142	1,010,904
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under employee plans, net (in shares)			1,001,255
Issuance of common stock under employee plans, net				(3,268)				(3,268)
Stock-based compensation				137,549				137,549
Net (loss) income						(47,117)		(47,117)
Foreign currency translation adjustments							(369)	(369)
Ending balance (in shares) at Jun. 30, 2021			65,674,346		20,220,227
Ending balance at Jun. 30, 2021			$ 1	$ 1,179,005	$ (155,947)	$ 74,867	$ (227)	$ 1,097,699

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (95,034)	$ (26,685)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization	8,582	5,811
Loss on disposal and abandonment of intangible assets	130	113
Loss on disposal and impairment of property and equipment, net	43	1,305
Realized and unrealized gains on strategic investments	(40,855)
Stock-based compensation	227,159	54,030
Deferred income taxes	(6,889)	(6,152)
Unrecognized tax benefits	47	612
Other noncash, net	5,760	2,596
Provision for expected credit losses	62	658
Change in assets and liabilities:
Accounts and notes receivable and contract assets	(3,988)	(9,375)
Inventory	(1,848)	(43,271)
Prepaid expenses and other assets	(13,320)	(8,551)
Accounts payable, accrued and other liabilities	(10,381)	16,708
Deferred revenue	25,647	5,224
Net cash provided by (used in) operating activities	95,115	(6,977)
Cash flows from investing activities:
Purchases of investments	(238,288)	(292,597)
Proceeds from call / maturity of investments	294,814	158,670
Proceeds from sale of strategic investments	14,546
Purchases of property and equipment	(24,031)	(7,551)
Proceeds from disposal of property and equipment	48	78
Purchases of intangible assets	(143)	(111)
Strategic investments	(20,500)	(4,700)
Net cash provided by (used in) investing activities	26,446	(146,211)
Cash flows from financing activities:
Net proceeds from equity offering	0	306,779
Proceeds from options exercised	0	295
Income and payroll tax payments for net-settled stock awards	(10,312)	(5,767)
Net cash provided by (used in) financing activities	(10,312)	301,307
Effect of exchange rate changes on cash and cash equivalents	(319)	(1,115)
Net increase in cash and cash equivalents	110,930	147,004
Cash and cash equivalents and restricted cash, beginning of period	155,551	172,355
Cash and cash equivalents and restricted cash, end of period	$ 266,481	$ 319,359

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Cash Flows - Supplemental - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Supplemental disclosures:
Cash and cash equivalents	$ 266,372	$ 319,253
Restricted cash (Note 1)	109	106
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	266,481	319,359
Cash paid for income taxes, net of refunds	5,295	6,327
Non-cash transactions
Property and equipment purchases in accounts payable and accrued liabilities	571	430
Investment purchases in accounts payable, net	$ 0	$ 10,400

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	1. Organization and Summary of Significant Accounting Policies Axon Enterprise, Inc. (“Axon,” the “Company,” "we," or "us") is a market-leading provider of law enforcement technology solutions. Our core mission is to protect life. We fulfill that mission through developing hardware and software products that advance the long term objectives of a) obsoleting the bullet, b) reducing social conflict, and c) enabling a fair and effective justice system. Our headquarters in Scottsdale, Arizona houses our executive management, sales, marketing, certain engineering, manufacturing, finance and other administrative support functions. Our global software hub is located in Seattle, Washington, and we also have subsidiaries and / or offices located in Australia, Canada, Finland, Germany, Hong Kong, India, Italy, the Netherlands, the United Kingdom, and Vietnam. The accompanying unaudited condensed consolidated financial statements include the accounts of Axon Enterprise, Inc. and our wholly owned subsidiaries. All material intercompany accounts, transactions, and profits have been eliminated. Basis of Presentation and Use of Estimates These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC. Certain information related to our organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in our annual consolidated financial statements for the year ended December 31, 2020, as filed on Form 10-K, with the exception of our adoption of certain accounting pronouncements which we describe below. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with our Form 10-K for the year ended December 31, 2020. The results of operations for the three months and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include: ● product warranty reserves, ● inventory valuation, ● revenue recognition, ● reserve for expected credit loss, ● valuation of goodwill, intangible and long-lived assets, ● recognition, measurement and valuation of current and deferred income taxes, ● stock-based compensation, and ● recognition and measurement of contingencies and accrued litigation expense. ​ Actual results could differ materially from those estimates. Segment Information Our operations are comprised of two reportable segments: the manufacture and sale of conducted electrical devices ("CEDs"), batteries, accessories, extended warranties and other products and services (the “TASER” segment); and the development, manufacture, and sale of software and sensors, which includes the sale of devices, wearables, applications, cloud and mobile products, and services (collectively, the “Software and Sensors” segment). In both segments, we report sales of products and services. Service revenue in both segments includes sales related to Axon Evidence. In the Software and Sensors segment, service revenue also includes other recurring cloud-hosted software revenue and related professional services. Collectively, this revenue is sometimes referred to as "Axon Cloud revenue." Reportable segments are determined based on discrete financial information reviewed by our Chief Executive Officer who is our chief operating decision maker ("CODM"). We organize and review operations based on products and services, and currently there are no operating segments that are aggregated. We perform an analysis of our reportable segments at least annually. Additional information related to our business segments is summarized in Note 14. Geographic Information and Major Customers / Suppliers For the three and six months ended June 30, 2021, no individual country outside the U.S. represented more than 10% of total net sales. Individual sales transactions in the international market are generally larger and occur more intermittently than in the domestic market due to the profile of our customers. For the three and six months ended June 30, 2021, no customer represented more than 10% of total net sales. At June 30, 2021 and December 31, 2020, no customer represented more than 10% of the aggregate balance of accounts and notes receivable and contract assets. We currently purchase both off the shelf and custom components, including, but not limited to, finished circuit boards, injection-molded plastic components, small machined parts, custom cartridge components, electronic components, and off the shelf sub-assemblies from suppliers located in the U.S., Canada, China, Israel, Republic of Korea, Mexico, Sri Lanka, and Taiwan. Although we currently obtain many of these components from single source suppliers, we own the injection molded component tooling, most of the designs, and the test fixtures used in their production for all custom components. As a result, we believe we could obtain alternative suppliers in most cases without incurring significant production delays. We also strategically hold safety stock levels on custom components to further reduce this risk. For off the shelf components, we believe that in most cases there are readily available alternative suppliers who can consistently meet our needs for these components. We acquire most of our components on a purchase order basis and do not have any significant long-term contracts with component suppliers. Income per Common Share Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution from outstanding stock options and unvested restricted stock units. The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2021 2020 2021 2020 Numerator for basic and diluted earnings per share: ​ ​ ​ ​ Net loss ​ $ (47,117) ​ $ (30,759) ​ $ (95,034) ​ $ (26,685) Denominator: ​ ​ ​ ​ ​ Weighted average shares outstanding ​ 65,166 ​ 60,346 ​ 64,604 ​ 59,977 Dilutive effect of stock-based awards ​ — ​ — ​ — ​ — Diluted weighted average shares outstanding ​ 65,166 ​ 60,346 ​ 64,604 ​ 59,977 Anti-dilutive stock-based awards excluded ​ 10,537 ​ 12,773 ​ 8,950 ​ 12,866 Net loss per common share: ​ ​ ​ ​ ​ Basic ​ $ (0.72) ​ $ (0.51) ​ $ (1.47) ​ $ (0.44) Diluted ​ $ (0.72) ​ $ (0.51) ​ $ (1.47) ​ $ (0.44) ​ Standard Warranties We warranty our CEDs, Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will repair or replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold when revenue is recorded for the related product. Future warranty costs are estimated based on historical data related to warranty claims and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure or other issue that could result in larger than anticipated warranty claims from customers. The warranty reserve is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. The warranty reserve is included in accrued liabilities on the accompanying condensed consolidated balance sheets. Changes in our estimated product warranty liabilities were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 ​ 2020 Balance, beginning of period ​ $ 769 ​ $ 1,476 Utilization of reserve ​ (481) ​ (350) Warranty expense (benefit) ​ 613 ​ (114) Balance, end of period ​ $ 901 ​ $ 1,012 ​ Fair Value Measurements and Financial Instruments We use the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: ● Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured. ● Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques. ● Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect our own assumptions about inputs that market participants would use in pricing an asset or liability. We have cash equivalents and investments, which at June 30, 2021 and December 31, 2020 were comprised of money market funds, certificates of deposit, commercial paper, corporate bonds, municipal bonds, U.S. Government agency bonds, and U.S. Treasury bills. Also included in cash equivalents and investments at December 31, 2020 were U.S. Treasury repurchase agreements and U.S. Treasury inflation-protected securities. See additional disclosure regarding the fair value of our cash equivalents and investments in Note 3. Included in the balance of other assets as of June 30, 2021 and December 31, 2020 was $5.1 million and $4.7 million, respectively, related to corporate-owned life insurance policies which are used to fund our deferred compensation plan. We determine the fair value of insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique. ​ We have strategic investments in three unconsolidated affiliates, which are included within other assets. The estimated fair value of the investments was determined based on Level 3 inputs. As of June 30, 2021, management estimated that the fair value of the investments equaled the carrying value. ​ Our financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the balance sheet. Restricted Cash Restricted cash balances as of June 30, 2021 and December 31, 2020 included $0.1 million primarily related to funds held in an international bank account for a country in which we are required to maintain a minimum balance to operate. Approximately half of the balance was included in prepaid expenses and other current assets on our condensed consolidated balance sheets, with the remainder included in other assets. Valuation of Goodwill, Intangibles and Long-lived Assets We evaluate whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets, excluding goodwill and intangible assets with indefinite useful lives, may warrant revision or that the remaining balance of these assets may not be recoverable. Such circumstances could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, we estimate the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows. We do not amortize goodwill and intangible assets with indefinite useful lives; rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. We perform our annual goodwill and intangible asset impairment tests in the fourth quarter of each year. Recently Issued Accounting Guidance Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Simplifying the Accounting for Income Taxes. Adoption of this ASU on January 1, 2021 did not have a material impact on our consolidated financial statements. ​ In January 2020, the FASB issued ASU No. 2020-01, Investments – Equity Securities (Topic 321), Investments – Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) – Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815 (a Consensus of the Emerging Issues Task Force). The guidance clarifies the interaction between ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities and the ASU on equity method investments. ASU 2016-01 provides companies with an alternative to measure certain equity securities without a readily determinable fair value at cost, minus impairment, if any, unless an observable transaction for an identical or similar security occurs. ASU 2020-01 clarifies that for purposes of applying the Topic 321 measurement alternative, an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting under Topic 323, immediately before applying or upon discontinuing the equity method. In addition, the new ASU provides direction that a company should not consider whether the underlying securities would be accounted for under the equity method or the fair value option when it is determining the accounting for certain forward contracts and purchased options, upon either settlement or exercise. Adoption of this ASU on January 1, 2021 did not have a material impact on our consolidated financial statements. ​ Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations.

Revenues

Revenues	6 Months Ended
	Jun. 30, 2021
Revenues
Revenues	2. Revenues Nature of Products and Services The following tables present our revenues by primary product and service offering (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2021 ​ Three Months Ended June 30, 2020 ​ ​ ​ Software and ​ ​ ​ ​ Software and ​ ​ ​ ​ TASER ​ Sensors ​ Total ​ TASER ​ Sensors ​ Total TASER 7 ​ $ 28,128 ​ ​ — ​ $ 28,128 ​ $ 11,588 ​ $ — ​ $ 11,588 TASER X26P ​ 9,569 ​ ​ — ​ 9,569 ​ 9,511 ​ — ​ 9,511 TASER X2 ​ 16,145 ​ ​ — ​ 16,145 ​ 16,832 ​ — ​ 16,832 TASER Pulse ​ 1,701 ​ ​ — ​ 1,701 ​ 2,193 ​ — ​ 2,193 Cartridges ​ 46,678 ​ ​ — ​ 46,678 ​ 23,772 ​ — ​ 23,772 Axon Body ​ — ​ ​ 19,927 ​ 19,927 ​ — ​ 11,844 ​ 11,844 Axon Flex ​ — ​ ​ 1,088 ​ 1,088 ​ — ​ 680 ​ 680 Axon Fleet ​ — ​ ​ 5,247 ​ 5,247 ​ — ​ 4,098 ​ 4,098 Axon Dock ​ — ​ ​ 5,509 ​ 5,509 ​ — ​ 4,055 ​ 4,055 Axon Evidence and cloud services ​ 1,702 ​ ​ 60,367 ​ 62,069 ​ 586 ​ 41,891 ​ 42,477 Extended warranties ​ 5,857 ​ ​ 8,149 ​ 14,006 ​ 5,098 ​ 5,735 ​ 10,833 Other ​ 2,748 ​ ​ 5,980 ​ 8,728 ​ 910 ​ 2,466 ​ 3,376 Total ​ $ 112,528 ​ $ 106,267 ​ $ 218,795 ​ $ 70,490 ​ $ 70,769 ​ $ 141,259 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ Six Months Ended June 30, 2020 ​ ​ ​ Software and ​ ​ ​ ​ Software and ​ ​ ​ ​ TASER ​ Sensors ​ Total ​ TASER ​ Sensors ​ Total TASER 7 ​ $ 62,119 ​ ​ — ​ $ 62,119 ​ $ 26,914 ​ $ — ​ $ 26,914 TASER X26P ​ 19,532 ​ ​ — ​ 19,532 ​ 20,572 ​ — ​ 20,572 TASER X2 ​ 28,923 ​ ​ — ​ 28,923 ​ 30,907 ​ — ​ 30,907 TASER Pulse ​ 3,906 ​ ​ — ​ 3,906 ​ 3,393 ​ — ​ 3,393 Cartridges ​ 77,096 ​ ​ — ​ 77,096 ​ 50,397 ​ — ​ 50,397 Axon Body ​ — ​ ​ 39,683 ​ 39,683 ​ — ​ 24,667 ​ 24,667 Axon Flex ​ — ​ ​ 1,993 ​ 1,993 ​ — ​ 1,863 ​ 1,863 Axon Fleet ​ — ​ ​ 9,010 ​ 9,010 ​ — ​ 8,873 ​ 8,873 Axon Dock ​ — ​ ​ 12,429 ​ 12,429 ​ — ​ 9,006 ​ 9,006 Axon Evidence and cloud services ​ 3,098 ​ ​ 112,661 ​ 115,759 ​ 1,084 ​ 81,045 ​ 82,129 Extended warranties ​ 11,503 ​ ​ 15,649 ​ 27,152 ​ 10,075 ​ 11,193 ​ 21,268 Other ​ 5,350 ​ ​ 10,862 ​ 16,212 ​ 3,043 ​ 5,389 ​ 8,432 Total ​ $ 211,527 ​ $ 202,287 ​ $ 413,814 ​ $ 146,385 ​ $ 142,036 ​ $ 288,421 ​ ​ The following table presents our revenues disaggregated by geography (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ ​ Six Months Ended June 30, ​ ​ 2021 ​ ​ 2020 ​ ​ 2021 ​ 2020 United States $ 164,908 75 % ​ $ 107,547 76 % ​ $ 325,294 79 % $ 225,010 78 % Other countries ​ 53,887 25 ​ ​ 33,712 24 ​ ​ 88,520 21 ​ 63,411 22 ​ Total ​ $ 218,795 100 % ​ $ 141,259 100 % ​ $ 413,814 100 % $ 288,421 100 % ​ Contract Balances The following table presents our contract assets, contract liabilities and certain information related to these balances as of and for the six months ended June 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ June 30, 2021 Contract assets, net ​ $ 118,252 Contract liabilities (deferred revenue) ​ 300,724 Revenue recognized in the period from: ​ Amounts included in contract liabilities at the beginning of the period ​ 111,375 ​ Contract liabilities (deferred revenue) consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ December 31, 2020 ​ Current Long-Term Total Current Long-Term Total Warranty: ​ ​ ​ ​ ​ ​ TASER ​ $ 12,467 ​ $ 16,937 ​ $ 29,404 ​ $ 11,635 ​ $ 16,953 ​ $ 28,588 Software and Sensors ​ 14,606 ​ 5,493 ​ 20,099 ​ 13,926 ​ 5,025 ​ 18,951 ​ ​ 27,073 ​ 22,430 ​ 49,503 ​ 25,561 ​ 21,978 ​ 47,539 Hardware: ​ ​ ​ ​ ​ ​ TASER ​ 22,408 ​ 11,498 ​ 33,906 ​ 16,314 ​ 14,304 ​ 30,618 Software and Sensors ​ 30,033 ​ 50,081 ​ 80,114 ​ 25,181 ​ 50,981 ​ 76,162 ​ ​ 52,441 ​ 61,579 ​ 114,020 ​ 41,495 ​ 65,285 ​ 106,780 Services: ​ ​ ​ ​ ​ ​ TASER ​ 1,200 ​ 3,455 ​ 4,655 ​ 996 ​ 1,554 ​ 2,550 Software and Sensors ​ 106,195 ​ 26,351 ​ 132,546 ​ 95,907 ​ 22,405 ​ 118,312 ​ ​ ​ 107,395 ​ ​ 29,806 ​ ​ 137,201 ​ ​ 96,903 ​ ​ 23,959 ​ ​ 120,862 Total ​ $ 186,909 ​ $ 113,815 ​ $ 300,724 ​ $ 163,959 ​ $ 111,222 ​ $ 275,181 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ December 31, 2020 ​ Current Long-Term Total Current Long-Term Total TASER ​ $ 36,075 ​ $ 31,890 ​ $ 67,965 ​ $ 28,945 ​ $ 32,811 ​ $ 61,756 Software and Sensors ​ 150,834 ​ 81,925 ​ 232,759 ​ 135,014 ​ 78,411 ​ 213,425 Total ​ $ 186,909 ​ $ 113,815 ​ $ 300,724 ​ $ 163,959 ​ $ 111,222 ​ $ 275,181 ​ Remaining Performance Obligations As of June 30, 2021, we had approximately $2.04 billion of remaining performance obligations, which included both recognized contract liabilities as well as amounts that will be invoiced and recognized in future periods. The remaining performance obligations are limited only to arrangements that meet the definition of a contract under Topic 606 as of June 30, 2021. We expect to recognize between 20% - 25% of this balance over the next twelve months, and generally expect the remainder to be recognized over the following five

Cash, Cash Equivalents and Inve

Cash, Cash Equivalents and Investments	6 Months Ended
	Jun. 30, 2021
Cash, Cash Equivalents and Investments
Cash, Cash Equivalents and Investments	3. Cash, Cash Equivalents and Investments The following tables summarize our cash, cash equivalents, and held-to-maturity investments at June 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2021 ​ ​ ​ Gross Gross ​ ​ Cash and ​ ​ ​ ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ ​ ​ ​ ​ Cash ​ Short-Term ​ Long-Term ​ ​ Cost ​ Gains ​ Losses ​ Fair Value ​ ​ Equivalents ​ Investments ​ Investments Cash ​ $ 199,426 ​ $ — ​ $ — ​ $ 199,426 ​ ​ $ 199,426 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1: ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ 48,052 ​ — ​ — ​ 48,052 ​ ​ 48,052 ​ — ​ — Agency bonds ​ 73,669 ​ 74 ​ — ​ 73,743 ​ ​ 5,500 ​ 60,169 ​ 8,000 Treasury bills ​ ​ 96,795 ​ ​ 2 ​ ​ (1) ​ ​ 96,796 ​ ​ ​ 12,600 ​ ​ 84,195 ​ ​ — Subtotal ​ 218,516 ​ 76 ​ (1) ​ 218,591 ​ ​ 66,152 ​ 144,364 ​ 8,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 2: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ State and municipal obligations ​ 101,610 ​ ​ 14 ​ ​ (27) ​ ​ 101,597 ​ ​ ​ 801 ​ ​ 87,596 ​ ​ 13,213 Certificates of deposit ​ ​ 500 ​ ​ — ​ ​ — ​ ​ 500 ​ ​ ​ — ​ ​ 500 ​ ​ — Corporate bonds ​ ​ 150,082 ​ ​ 105 ​ ​ (32) ​ ​ 150,155 ​ ​ ​ — ​ ​ 122,607 ​ ​ 27,475 Commercial paper ​ 33,983 ​ ​ — ​ ​ — ​ ​ 33,983 ​ ​ ​ — ​ ​ 33,983 ​ ​ — Subtotal ​ 286,175 ​ ​ 119 ​ ​ (59) ​ ​ 286,235 ​ ​ ​ 801 ​ ​ 244,686 ​ ​ 40,688 Total ​ $ 704,117 ​ $ 195 ​ $ (60) ​ $ 704,252 ​ ​ ​ 266,379 ​ ​ 389,050 ​ ​ 48,688 Expected credit loss reserve ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (7) ​ ​ (155) ​ ​ (19) Total, net of reserve for expected credit losses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 266,372 ​ $ 388,895 ​ $ 48,669 ​ ​ Because we do not have any history of losses for our held-to-maturity investments, o ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 ​ ​ ​ Gross Gross ​ ​ Cash and ​ ​ ​ ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ ​ ​ ​ ​ Cash ​ Short-Term ​ Long-Term ​ ​ Cost ​ Gains ​ Losses ​ Fair Value ​ ​ Equivalents ​ Investments ​ Investments Cash ​ $ 116,107 ​ $ — ​ $ — ​ $ 116,107 ​ ​ $ 116,107 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1: ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ 23,611 ​ — ​ — ​ 23,611 ​ ​ 23,611 ​ — ​ — Agency bonds ​ 63,794 ​ 122 ​ — ​ 63,916 ​ ​ — ​ 23,794 ​ 40,000 Treasury Bills ​ ​ 96,384 ​ ​ 6 ​ ​ — ​ ​ 96,390 ​ ​ ​ ​ ​ ​ 96,384 ​ ​ ​ Subtotal ​ 183,789 ​ 128 ​ — ​ 183,917 ​ ​ 23,611 ​ 120,178 ​ 40,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 2: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ State and municipal obligations ​ ​ 77,130 ​ ​ 25 ​ ​ (28) ​ ​ 77,127 ​ ​ ​ — ​ ​ 66,519 ​ ​ 10,611 Certificates of deposit ​ ​ 500 ​ ​ — ​ ​ — ​ ​ 500 ​ ​ ​ — ​ ​ 500 ​ ​ — Corporate bonds ​ ​ 212,825 ​ ​ 232 ​ ​ (100) ​ ​ 212,957 ​ ​ ​ 2,525 ​ ​ 170,205 ​ ​ 40,095 U.S. Treasury repurchase agreements ​ ​ 13,200 ​ ​ — ​ ​ — ​ ​ 13,200 ​ ​ ​ 13,200 ​ ​ — ​ ​ — Treasury inflation-protected securities ​ ​ 3,291 ​ ​ 16 ​ ​ — ​ ​ 3,307 ​ ​ ​ — ​ ​ 3,291 ​ ​ ​ Commercial paper ​ ​ 45,974 ​ ​ — ​ ​ — ​ ​ 45,974 ​ ​ ​ ​ ​ ​ 45,974 ​ ​ — Subtotal ​ ​ 352,920 ​ ​ 273 ​ ​ (128) ​ ​ 353,065 ​ ​ ​ 15,725 ​ ​ 286,489 ​ ​ 50,706 Total ​ $ 652,816 ​ $ 401 ​ $ (128) ​ $ 653,089 ​ ​ ​ 155,443 ​ ​ 406,667 ​ ​ 90,706 Expected credit loss reserve ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (3) ​ ​ (142) ​ ​ (25) Total, net of reserve for expected credit losses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 155,440 ​ $ 406,525 ​ $ 90,681 ​

Expected Credit Losses

Expected Credit Losses	6 Months Ended
	Jun. 30, 2021
Expected Credit Losses
Expected Credit Losses	4. Expected Credit Losses We are exposed to credit losses primarily through sales of products and services. Our expected loss allowance methodology for accounts receivable, notes receivable, and contract assets is developed using historical collection experience, published or estimated credit default rates for entities that represent our customer base, current and future economic and market conditions and a review of the current status of customers' trade accounts receivables. Additionally, specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. Our monitoring activities include account reconciliation, dispute resolution, payment confirmation, consideration of customers' financial condition and macroeconomic conditions. Balances are written off when determined to be uncollectible. ​ We considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and recorded an additional reserve for credit loss of approximately $1.0 million as of June 30, 2021. ​ We review receivables for U.S. and international customers separately to better reflect different published credit default rates and economic and market conditions. ​ The following table provides a roll-forward of the allowance for expected credit losses that is deducted from the amortized cost basis of accounts receivable, notes receivable, and contract assets to present the net amount expected to be collected (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ ​ ​ United States ​ ​ Other countries ​ ​ Total Balance, beginning of period ​ $ 2,902 ​ $ 474 ​ $ 3,376 Provision for expected credit losses ​ ​ 256 ​ ​ (130) ​ ​ 126 Amounts written off charged against the allowance ​ ​ (54) ​ ​ - ​ ​ (54) Other, including dispositions and foreign currency translation ​ 78 ​ (9) ​ 69 Balance, end of period ​ $ 3,182 ​ $ 335 ​ $ 3,517 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 ​ 2020 Accounts receivable and notes receivable, current ​ $ 1,973 ​ $ 2,105 Contract assets, net ​ 1,186 ​ 794 Long-term notes receivable, net of current portion ​ 358 ​ 477 Total allowance for expected credit losses on customer receivables ​ $ 3,517 ​ $ 3,376 ​

Inventory

Inventory	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Inventory	5. Inventory Inventories are stated at the lower of cost and net realizable value. Cost is determined using the weighted average cost of raw materials, which approximates the first-in, first-out (“FIFO”) method and includes allocations of manufacturing labor and overhead. Provisions are made to reduce excess, obsolete or slow-moving inventories to their net realizable value. Inventory consisted of the following at June 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 December 31, 2020 Raw materials ​ $ 35,935 ​ $ 39,194 Finished goods ​ 55,804 ​ 50,764 Total inventory ​ $ 91,739 ​ $ 89,958 ​

Strategic Investments

Strategic Investments	6 Months Ended
	Jun. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Strategic Investments	6. Strategic Investments Strategic investments include investments in a number of non-public technology-driven companies. We account for strategic investments under the ASC 321 measurement alternative for equity securities without readily determinable fair values, as there are no quoted market prices for the investments. The investments are measured at cost less impairment, adjusted for observable price changes and are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. ​ In conjunction with one of our strategic investments, we have the ability to commit additional capital over time through warrants where the exercisability and exercise prices are conditional on the achievement of certain partnership performance metrics. The amount reflected in other assets represents the fair value of the preferred stock warrants as of June 30, 2021. The following tables provides a roll-forward of the balance of strategic investments (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ ​ Strategic investments ​ Warrants for strategic investment ​ Total Balance, beginning of period ​ $ 9,500 ​ $ 2,211 ​ $ 11,711 Investments ​ ​ 20,500 ​ ​ - ​ ​ 20,500 Observable price changes ​ ​ 40,321 ​ ​ 534 ​ ​ 40,855 Sales ​ ​ (14,546) ​ ​ - ​ ​ (14,546) Balance, end of period ​ $ 55,775 ​ $ 2,745 ​ $ 58,520 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Inception to date ​ ​ Strategic investments ​ Warrants for strategic investment ​ Total Investments ​ $ 27,568 ​ $ 2,588 ​ $ 30,156 Observable price changes ​ ​ 42,753 ​ ​ 157 ​ ​ 42,910 Sales ​ ​ (14,546) ​ ​ - ​ ​ (14,546) Balance, end of period ​ $ 55,775 ​ $ 2,745 ​ $ 58,520 ​ During the period ended June 30, 2021, certain of our strategic investees issued new equity to us and/or other investors. These events represented observable price changes for our existing investments and related warrants. Of the total observable price changes, we realized a gain of approximately $12.3 million on the sale of a portion of one of our existing investments. The estimated fair value of the retained existing investments was calculated using valuation techniques that included both observable and unobservable inputs, and was lower than the issue per share of the new equity issued by the strategic investee because of different characteristics of the newly issued equity instruments compared to our existing investments. The valuation techniques included both Level 2 and Level 3 inputs as defined by ASC Topic 820.

Other Long-Term Assets

Other Long-Term Assets	6 Months Ended
	Jun. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Long-Term Assets	7. Other Long-Term Assets Other long-term assets consisted of the following at June 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 December 31, 2020 Cash surrender value of corporate-owned life insurance policies ​ $ 5,055 ​ $ 4,654 Deferred commissions (1) ​ 36,489 ​ 32,455 Restricted cash ​ 60 ​ 62 Operating lease assets ​ 26,885 ​ 22,308 Prepaid expenses, deposits and other ​ 15,755 ​ 8,727 Total other long-term assets ​ $ 84,244 ​ $ 68,206 (1) Represents the incremental costs of obtaining contracts with customers, which consist primarily of sales commissions. These costs are ascribed to or allocated to the underlying performance obligations in the contracts and amortized consistent with the recognition timing of the revenue for the underlying performance obligations.

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
Accrued Liabilities	8. Accrued Liabilities Accrued liabilities consisted of the following at June 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 December 31, 2020 Accrued salaries, benefits and bonus ​ $ 39,487 ​ $ 36,892 Accrued professional, consulting and lobbying fees ​ 1,201 ​ 3,055 Accrued warranty expense ​ 901 ​ 769 Accrued income and other taxes ​ ​ 3,780 ​ ​ 3,848 Accrued inventory in transit ​ 10,979 ​ 4,597 Other accrued expenses ​ 10,560 ​ 10,682 Accrued liabilities ​ $ 66,908 ​ $ 59,843 ​

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes We file income tax returns for federal purposes and in many states, as well as in multiple foreign jurisdictions. Our tax filings remain subject to examination by applicable tax authorities for a certain length of time, generally three to four years, following the tax year to which these filings relate. During the second quarter of 2020 we began an audit with the State of California for our fiscal year 2016 and 2017 state tax returns, which was completed during Q2 2021. During the second quarter of 2021, an audit with the State of Illinois for our fiscal year 2018 state return commenced. Additionally, we have been notified that an audit may commence for Axon Public Safety Southeast Asia LLC, our entity in Vietnam. The tax period has not yet been defined. On March 11, 2021, the U.S. federal government enacted the American Rescue Plan Act. This act is an emergency economic stimulus package in response to the COVID-19 pandemic, which, among other things, contains numerous income tax provisions. We are continuing to evaluate the implications of the American Rescue Plan Act, but its impact on the financial statements and related disclosures is not expected to be material. Deferred Tax Assets Net deferred income tax assets at June 30, 2021, primarily include R&D tax credits, stock-based compensation expense, deferred revenue, accruals and reserves, and net operating losses, partially offset by accelerated depreciation expense and valuation allowance reserve. Our total net deferred tax assets at June 30, 2021 were $51.9 million. In preparing our condensed consolidated financial statements, management assesses the likelihood that its deferred tax assets will be realized from future taxable income. In evaluating our ability to recover our deferred income tax assets, management considers all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction by jurisdiction basis. A valuation allowance is established if it is determined that it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Management exercises significant judgment in determining our provisions for income taxes, our deferred tax assets and liabilities, and our future taxable income for purposes of assessing our ability to utilize any future tax benefit from our deferred tax assets. As of June 30, 2021, we continue to demonstrate three-year cumulative pre-tax income in the U.S. federal and state tax jurisdictions; however, we have Arizona R&D tax credits expiring unutilized each year. Therefore, management has concluded that it is more likely than not that our Arizona R&D deferred tax asset will not be realized. In Australia, we have determined that sufficient deferred tax liabilities will reverse in order to realize all assets except one long-lived intangible where there is not an expectation that the asset may be realized. Therefore, we continue to recognize a partial valuation allowance for Australia. We complete R&D tax credit studies for each year that an R&D tax credit is claimed for federal, Arizona, and California income tax purposes. Management has made the determination that it is more likely than not that the full benefit of the R&D tax credit will not be sustained on examination and recorded a liability for unrecognized tax benefits of $7.6 million as of June 30, 2021. Should the unrecognized benefit of $7.6 million be recognized, our effective tax rate would be favorably impacted. Approximately $3.3 million of the unrecognized tax benefit associated with R&D credits has been netted against the R&D deferred tax asset. Effective Tax Rate Our overall effective tax rate for the six months ended June 30, 2021, after discrete period adjustments, was 6.4%. Before discrete adjustments, the tax rate was (19.1%), which differs from the federal statutory rate, primarily due to the impact of the executive compensation limitation under Internal Revenue Code ("IRC") Section 162(m), partially offset by R&D tax credits, on a projected pre-tax loss for the year. The effective tax rate was favorably impacted by a $25.7 million discrete tax benefit primarily associated with windfalls related to stock-based compensation for restricted stock units (“RSUs”) or performance stock units (“PSUs”) that vested during the six months ended June 30, 2021.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Stockholders' Equity	10. Stockholders’ Equity Performance-based stock awards We have issued performance-based stock options and performance-based RSUs, the vesting of which is generally contingent upon the achievement of certain performance criteria related to our operating performance, as well as successful and timely development and market acceptance of future product introductions. In addition, certain of the performance RSUs have additional service requirements subsequent to the achievement of the performance criteria. Compensation expense is recognized over the requisite service period, which is defined as the longest explicit, implicit or derived service period based on management’s estimate of the probability of the performance criteria being satisfied, adjusted at each balance sheet date. For both service-based and performance-based RSUs, we account for forfeitures as they occur as a reduction to stock-based compensation expense and additional paid-in-capital. For performance-based options with a vesting schedule based entirely on the attainment of both performance and market conditions, stock-based compensation expense is recognized for each pair of performance and market conditions over the longer of the expected achievement period of the performance and market conditions, beginning at the point in time that the relevant performance condition is considered probable of achievement. The fair value of such awards is estimated on the grant date using Monte Carlo simulations. CEO Performance Award On May 24, 2018, our stockholders approved the Board of Directors’ grant of 6,365,856 stock option awards to Patrick W. Smith, our CEO (the “CEO Performance Award”). The CEO Performance Award consists of 12 vesting tranches with a vesting schedule based entirely on the attainment of both operational goals (performance conditions) and market capitalization goals (market conditions), assuming continued employment either as the CEO or as both Executive Chairman and Chief Product Officer and service through each attainment date. Each of the 12 vesting tranches of the CEO Performance Award have a 10-year and other income (such as dividends) earned on investments in marketable securities, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense. ​ ​ ​ ​ ​ Eight Separate Adjusted EBITDA (CEO Eight Separate Revenue Goals (1) ​ Performance Award) Goals (in thousands) ​ (in thousands) Goal #1, $710,058 Goal #9, $125,000 Goal #2, $860,058 Goal #10, $155,000 Goal #3, $1,010,058 Goal #11, $175,000 Goal #4, $1,210,058 Goal #12, $190,000 Goal #5, $1,410,058 Goal #13, $200,000 Goal #6, $1,610,058 Goal #14, $210,000 Goal #7, $1,810,058 Goal #15, $220,000 Goal #8, $2,010,058 Goal #16, $230,000 (1) In connection with the business acquisition that was completed during the three months ended June 30, 2018, the revenue goals were adjusted for the acquiree’s Target Revenue, as defined in the CEO Performance Award agreement. As of June 30, 2021, the following operational goals were achieved, with vesting of the related tranches pending certification by the Compensation Committee: ● Adjusted EBITDA (CEO Performance Award) of $175.0 million, $190.0 million, $200.0 million, $210.0 million, and $220.0 million. As of June 30, 2021, the following operational goals were considered probable of achievement: ● Adjusted EBITDA (CEO Performance Award) of $230.0 million. ● Total revenue of $860.1 million, $1,010.1 million, and $1,210.1 million; and As of June 30, 2021, the following operational goals were previously achieved and the related tranches vested: ● Adjusted EBITDA (CEO Performance Award) of $125.0 million and $155.0 million ● Total revenue of $710.1 million Stock-based compensation expense associated with the CEO Performance Award is recognized over the requisite service period, which is defined as the longest explicit, implicit or derived service period, based on management’s estimate of the probability and timing of the performance criteria being satisfied, adjusted at each balance sheet date. Expense recognition begins at the point in time when the relevant operational goal is considered probable of being met. The probability of attaining an operational goal and the expected attainment date for meeting a probable operational goal are based on a subjective assessment of our forward-looking financial projections, taking into consideration statistical analysis when considered appropriate. The statistical model and the assessment that determine the estimated attainment dates are subject to a number of estimated inputs, including expected volatility rates, management’s forward-looking financial projections, in particular for operational goals that are anticipated to be attained in the near future, and adjustment of other estimates based on the passage of time. Beginning with the three months ended June 30, 2021, management discontinued consideration of the statistical model based on actual and anticipated attainment of the remaining operational goals. compensation expense as a result of updated estimates for the CEO Performance Award and eXponential Stock Performance Plan (discussed below). The first eight market capitalization goals have been achieved as of June 30, 2021. As of June 30, 2021, 1.6 million stock options have vested. As twelve operational goals are considered probable of achievement, we recorded stock-based compensation expense of $204.2 million related to the CEO Performance Award from the Grant Date through June 30, 2021. The number of stock options that would vest related to the remaining unvested tranches is approximately 4.8 million shares. As of June 30, 2021, we had $41.7 million of total unrecognized stock-based compensation expense for the performance goals that were considered probable of achievement, which will be recognized over a weighted-average period of 1.57 eXponential Stock Performance Plan On February 12, 2019, our shareholders approved the 2019 Stock Incentive Plan (the “2019 Plan”), which was adopted by the Board of Directors to reserve a sufficient number of shares to facilitate our eXponential Stock Performance Plan (“XSPP”) and grants of eXponential Stock Units (“XSUs”) under the plan. Initial awards under the plan were granted in January 2019, with additional employee awards granted since that date. During the three and six months ended June 30, 2021 we granted an additional twenty three thirty three The XSUs are grants of RSUs, each with a term of approximately nine years, that vest in 12 equal tranches. Each of the 12 tranches will vest upon certification by the Compensation Committee of the Board of Directors that both (i) the market capitalization goal for such tranche, which begins at $2.5 billion for the first tranche and increases by increments of $1.0 billion thereafter, and (ii) any one of eight operational goals focused on revenue or eight operational goals focused on Adjusted EBITDA (CEO Performance Award) have been met for the previous four consecutive fiscal quarters. Beginning with the quarter ended June 30, 2021, new XSU grants are divided into a reduced number of tranches depending on employee eligibility and current market capitalization attainment. The XSPP contains an anti-dilution provision incorporated into the plan based on shareholder feedback, which affects the calculation of the market capitalization goals in the plan. The plan defines a maximum number of shares outstanding that may be used in the calculation of the market capitalization goals (the “XSU Maximum”). If the actual number of shares outstanding exceeds the XSU Maximum guardrail, then the lower pre-defined number of shares in the XSU Maximum, rather than the higher actual number of shares outstanding, is used to calculate market capitalization for the determination of the market capitalization goals in the XSPP, which, together with the operational goals, determines whether XSUs vest for participating employees. The XSU Maximum is defined as the actual number of shares outstanding on the original XSU grant date of January 2, 2019, increased by a 3% annual rate over the term of the XSPP and by shares issued upon the exercise of CEO Performance Award options. The XSU Maximum is also adjusted for acquisitions, spin-offs or other changes in the number of outstanding shares of common stock, if such changes have a corresponding adjustment on the market capitalization goals. New shares issued for any other reasons, including shares issued upon vesting of XSUs, RSUs, and Performance Stock Units (“PSUs”) as well as shares issued to raise capital through equity issuances or in other transactions, do not increase the XSU Maximum. The market capitalization and operational goals are identical to the CEO Performance Award, but a different number of shares is used to calculate the market capitalization goals if shares outstanding exceed the XSU Maximum. Additionally, because the grant date is different than that of the CEO Performance Award, the measurement period for market capitalization is not identical. As of June 30, 2021, actual shares outstanding exceeded the XSU Maximum as a result of the common stock offering completed in June 2020. Accordingly, market capitalization as calculated for the purposes of achieving additional goals uses the lower XSU Maximum share amount rather than actual shares outstanding. The first eight market capitalization goals have been achieved as of June 30, 2021. The first XSU tranche vested in March 2021, and the second and third tranches vested in May 2021. As all twelve operational goals are considered probable of achievement, we recorded stock-based compensation expense of $151.4 million related to the XSU awards from their respective grant dates through June 30, 2021. The number of XSU awards that would vest related to the remaining nine tranches is approximately 4.0 million shares. As of June 30, 2021, we had $42.3 million of total unrecognized stock-based compensation expense, which will be recognized over a weighted-average period of 2.20 years. Restricted Stock Units The following table summarizes RSU activity for the six months ended June 30, 2021 (number of units and aggregate intrinsic value in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Weighted Average Aggregate ​ ​ Units ​ Grant-Date Fair Value ​ Intrinsic Value Units outstanding, beginning of year 1,107 ​ $ 76.10 ​ Granted 98 ​ 149.92 ​ Released (276) ​ 51.65 ​ Forfeited (64) ​ 98.43 ​ Units outstanding, end of period 865 ​ 90.59 ​ $ 152,892 ​ Aggregate intrinsic value represents our closing stock price on the last trading day of the period, which was $176.80 per share, multiplied by the number of RSUs outstanding. As of June 30, 2021, there was $57.4 million in unrecognized compensation costs related to RSUs under our stock plans for shares that are expected to vest. We expect to recognize the cost related to the RSUs over a weighted average period of 2.10 years. RSUs are released when vesting requirements are met. Certain RSUs that vested in the six months ended June 30, 2021 were net-share settled such that we withheld shares to cover the employees’ tax obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total shares withheld related to RSUs were forty six Performance Stock Units The following table summarizes PSU activity, inclusive of XSUs, for the six months ended June 30, 2021 (number of units and aggregate intrinsic value in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Weighted Average Aggregate ​ ​ Units ​ Grant-Date Fair Value ​ Intrinsic Value Units outstanding, beginning of year 5,618 ​ $ 35.71 ​ Granted 225 ​ 50.00 ​ Released (1,696) ​ 41.20 ​ Forfeited (60) ​ 35.80 ​ Units outstanding, end of period 4,087 ​ 34.22 ​ $ 722,593 ​ Aggregate intrinsic value represents our closing stock price on the last trading day of the period, which was $176.80 per share, multiplied by the number of PSUs outstanding. As of June 30, 2021, there was $44.8 million in unrecognized compensation costs related to PSUs under our stock plans for shares that are expected to vest. We expect to recognize the cost related to the PSUs over a weighted average period of 2.22 years. PSUs are released when vesting requirements are met. As of June 30, 2021, the performance criteria had been met for approximately 2.2 million of the 4.1 million PSUs outstanding. On March 8 and May 17, 2021, the Compensation Committee of our Board of Directors approved waivers of the holding period requirements for each XSPP participant who is an Arizona resident and elected to receive XSUs in lieu of On-Target Earnings. This waiver releases the holding period requirements to allow participants the ability to choose to sell a portion of their vested shares to satisfy new income tax obligations pursuant to Arizona Proposition 208, which was passed in the November 2020 state-wide election. This waiver applied only to 4% of the XSUs for the impacted participants which vested on March 8 and May 17, 2021, amounting to approximately 36 thousand shares. The remainder of the shares not sold to satisfy tax obligations are subject to a 2.5 year minimum holding period. We accounted for this change as a Type I modification under ASC 718 since there was no impact on attainment of the operational or market capitalization goals. We recognized additional stock-based compensation expense of $0.5 million and $0.9 million for the three months and six months ended June 30, 2021, respectively, because of this modification. Certain PSUs that vested in the six months ended June 30, 2021 were net-share settled such that we withheld shares to cover the employees’ tax obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total shares withheld related to PSUs were approximately nineteen thousand and had a value of $2.8 million on their respective vesting dates as determined by the closing stock price on such dates. Payments for the employees’ tax obligations are reflected as a financing activity within the condensed consolidated statements of cash flows. We record a liability for the tax withholding to be paid by us as a reduction to additional paid-in capital. Stock Option Activity The following table summarizes stock option activity for the six months ended June 30, 2021 (number of units and aggregate intrinsic value in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ Weighted ​ Average ​ ​ ​ ​ ​ Number ​ Average ​ Remaining ​ ​ ​ ​ ​ of ​ Exercise ​ Contractual ​ Aggregate ​ ​ Options ​ Price ​ Life (years) ​ Intrinsic Value Options outstanding, beginning of year 6,366 ​ $ 28.58 ​ Granted — ​ ​ — ​ Exercised — ​ ​ — ​ Expired / terminated — ​ ​ — ​ Options outstanding, end of period 6,366 ​ 28.58 6.66 ​ $ 943,547 Options exercisable, end of period 4,243 ​ 28.58 6.66 ​ 629,031 ​ Aggregate intrinsic value represents the difference between the exercise price of the underlying stock option awards and the closing market price of our common stock of $176.80 on June 30, 2021. There were no options exercised for the six months ended June 30, 2021. The intrinsic value of options exercised for the six months ended June 30, 2020 was $5.1 million. As of June 30, 2021, total options outstanding included 2.1 million unvested performance-based stock options, which relate to the CEO Performance Award and are probable of achievement. Stock-based Compensation Expense The following table summarizes the composition of stock-based compensation expense for the three and six months ended June 30, 2021 and 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2021 2020 2021 2020 Cost of products sold and services delivered ​ $ 1,838 ​ $ 836 ​ $ 3,327 ​ $ 1,426 Sales, general and administrative expenses ​ 114,089 ​ 26,766 ​ 185,104 ​ 41,736 Research and development expenses ​ 21,622 ​ 6,233 ​ 38,728 ​ 10,868 Total stock-based compensation expense ​ $ 137,549 ​ $ 33,835 ​ $ 227,159 ​ $ 54,030 ​ Stock Incentive Plan In February 2019, our shareholders approved the 2019 Plan authorizing an additional 6.0 million shares, plus remaining available shares under prior plans, for issuance under the new plan. Combined with the legacy stock incentive plans, there are 1.8 million shares available for grant as of June 30, 2021. Stock Repurchase Plan In February 2016, our Board of Directors authorized a stock repurchase program to acquire up to $50.0 million of our outstanding common stock subject to stock market conditions and corporate considerations. During the six months ended June 30, 2021 and 2020, no common shares were purchased under the program. As of June 30, 2021, $16.3 million remains available under the plan for future purchases. Any future purchases will be discretionary.

Line of Credit

Line of Credit	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Line of Credit	11. Line of Credit We have a $50.0 million unsecured revolving line of credit with a domestic bank, of which $20.0 million is available for letters of credit. The credit agreement matures on December 31, 2023 and has an accordion feature which allows for an increase in the total line of credit up to $100.0 million, subject to certain conditions, including the availability of additional bank commitments. At June 30, 2021 and December 31, 2020, there were no borrowings under the line. Under the terms of the line of credit, available borrowings are reduced by outstanding letters of credit. As of June 30, 2021, we had letters of credit outstanding of approximately $6.1 million under the facility and available borrowing of $43.9 million, excluding amounts available under the accordion feature. Advances under the line of credit bear interest at LIBOR plus 1.0 to 1.5% per year determined in accordance with a pricing grid based on our funded debt to earnings before interest, taxes, depreciation and amortization ("EBITDA") ratio. We are required to comply with a maximum funded debt to EBITDA ratio of no greater than 2.50 to 1.00 based upon a trailing four fiscal quarter period. At June 30, 2021, our funded debt to EBITDA ratio was 0.00 to 1.00.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Product Litigation As a manufacturer of weapons and other law enforcement tools used in high-risk field environments, we are often the subject of products liability litigation concerning the use of our products. We are currently named as a defendant in four lawsuits in which the plaintiffs allege either wrongful death or personal injury in situations in which a TASER CED was used by law enforcement officers in connection with arrests or training. While the facts vary from case to case, these product liability claims typically allege defective product design, manufacturing, and/or failure to warn. They seek compensatory and sometimes punitive damages, often in unspecified amounts. ​ We continue to aggressively defend all product litigation. As a general rule, it is our policy not to settle suspect injury or death cases. Exceptions are sometimes made where the settlement is strategically beneficial to us. Due to the confidential nature of our litigation strategy and the confidentiality agreements that are executed in the event of a settlement, we do not identify or comment on specific settlements by case or amount. Based on current information, we do not believe that the outcome of any such legal proceeding will have a material effect on our financial position, results of operations, or cash flows. We are self-insured for the first $5.0 million of any product claim made after 2014. No judgment or settlement has ever exceeded this amount in any products case. We continue to maintain product liability insurance coverage, including an insurance policy fronting arrangement, above our self-insured retention with various limits depending on the policy period. The litigation information in this note is current through the date of these financial statements. U.S. Federal Trade Commission Litigation The U.S. Federal Trade Commission (“FTC”) filed an enforcement action on January 3, 2020 regarding Axon’s May 2018 acquisition of Vievu LLC from Safariland LLC. The FTC alleges the merger was anticompetitive and adversely affected the body worn camera (“BWC”) and digital evidence management systems (“DEMS”) market for “large metropolitan police departments.” The administrative hearing is presently stayed by the Ninth Circuit (see below). If ultimately successful, the FTC may require Axon to divest Vievu and other assets or take other remedial measures, any of which could be material to Axon. We are vigorously defending the matter. At this time, we cannot predict the eventual scope, duration, or outcome of the proceeding and accordingly we have not recorded any liability in the accompanying consolidated financial statements. Prior to the FTC’s enforcement action, Axon sued the FTC in federal court in the District of Arizona for declaratory and injunctive relief alleging the FTC’s structure and administrative processes violate Article II of the U.S. Constitution and our Fifth Amendment rights to due process and equal protection. The district court dismissed the action, without prejudice, for lack of jurisdiction. The Ninth Circuit affirmed in a split decision but granted Axon’s motion to stay the appellate mandate pending the filing of its petition for certiorari with the U.S. Supreme Court. That petition was filed July 20, 2021. The FTC’s administrative case will remain stayed pending resolution of the Supreme Court proceedings. In parallel to these matters, we are evaluating strategic alternatives to litigation, which we might pursue if determined to be in the best interests of shareholders and customers. This could include a divestiture of the Vievu entity and/or related assets and the licensure of certain intellectual and other intangible property. While we continue to believe the acquisition of Vievu was lawful and a benefit to Vievu’s customers, the cost, risk and distraction of protracted litigation merit consideration of settlement if achievable on terms agreeable to the FTC and the company. General From time to time, we are notified that we may be a party to a lawsuit or that a claim is being made against us. It is our policy to not disclose the specifics of any claim or threatened lawsuit until the summons and complaint are actually served on us. After carefully assessing the claim, and assuming we determine that we are not at fault or we disagree with the damages or relief demanded, we vigorously defend any lawsuit filed against us. We record a liability when losses are deemed probable and reasonably estimable. When losses are deemed reasonably possible but not probable, we determine whether it is possible to provide an estimate of the amount of the loss or range of possible losses for the claim, if material for disclosure. In evaluating matters for accrual and disclosure purposes, we take into consideration factors such as our historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of our prevailing, the availability of insurance, and the severity of any potential loss. We reevaluate and update accruals as matters progress over time. ​ Based on our assessment of outstanding litigation and claims as of June 30, 2021, we have determined that it is not reasonably possible that these lawsuits will individually, or in the aggregate, materially affect our results of operations, financial condition or cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the resolution of these matters will be covered by our insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on our operating results, financial condition or cash flows. Off-Balance Sheet Arrangements Under certain circumstances, we use letters of credit and surety bonds to guarantee our performance under various contracts, principally in connection with the installation and integration of Axon cameras and related technologies. Certain of our letters of credit and surety bonds have stated expiration dates with others being released as the contractual performance terms are completed. At June 30, 2021, we had outstanding letters of credit of $6.1 million that are expected to expire in September 2021 and June 2022. We also had outstanding letters of credit and bank guarantees of $2.0 million that do not draw against our credit facility. The outstanding letters of credit are expected to expire in March 2022 and May 2022. Additionally, we had $21.5 million of outstanding surety bonds at June 30, 2021, with $0.4 million expiring in 2021, $3.1 million expiring in 2022, $7.5 million expiring in 2023 and the remaining $10.5 million expiring in 2024. Share Purchase Agreement On April 8, 2021, we entered into a Share Purchase Agreement with Cellebrite DI Ltd. ("Cellebrite") and Cellebrite’s shareholders, pursuant to which we have agreed to purchase, and Cellebrite has agreed to sell, an aggregate of 9,000,000 shares of common stock of Cellebrite, for a purchase price of $10.00 per share and an aggregate purchase price of $90,000,000. This investment is being made in connection with Cellebrite’s business combination with TWC Tech Holdings II Corp. (“TWC Tech Holdings”), a publicly traded special purpose acquisition company, pursuant to the definitive business combination agreement and plan of merger (the “Business Combination”). The obligations to consummate the transactions contemplated by the Share Purchase Agreement are conditioned upon, among other things, customary closing conditions and the consummation of the Business Combination and other transactions contemplated by the plan of merger between Cellebrite and TWC Tech Holdings.

Employee Benefit Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2021
Retirement Benefits [Abstract]
Employee Benefit Plans	13. Employee Benefit Plans We have a defined contribution 401(k) plan for eligible employees, which is qualified under Sections 401(a) and 401(k) of the Internal Revenue Code of 1986, as amended. Employees are entitled to make tax-deferred contributions of up to the maximum amount allowed by law of their eligible compensation. We also have a non-qualified deferred compensation plan for certain executives, employees and non-employee directors through which participants may elect to postpone the receipt and taxation of a portion of their compensation, including stock-based compensation, received from us. The non-qualified deferred compensation plan allows eligible participants to defer up to 80% of their base salary and up to 100% of other types of compensation. The plan also allows for matching and discretionary employer contributions. Employee deferrals are deemed 100% vested upon contribution. Distributions from the plan are made upon retirement, death, separation of service, specified date or upon the occurrence of an unforeseeable emergency. Distributions can be paid in a variety of forms from lump sum to installments over a period of years. Participants in the plan are entitled to select from a wide variety of investments available under the plan and are allocated gains or losses based upon the performance of the investments selected by the participant. All gains or losses are allocated fully to plan participants and we do not guarantee a rate of return on deferred balances. Assets related to this plan consist of corporate-owned life insurance contracts and are included in other assets in the condensed consolidated balance sheets; see Note 7 for balances. Participants have no rights or claims with respect to any plan assets and any such assets are subject to the claims of our general creditors. Contributions to the plans are made by both the employee and us. Our contributions to the 401(k) plan are based on the level of employee contributions and are immediately vested. Future matching contributions to the plans are at our sole discretion. We also sponsor defined contribution plans in Australia, Canada, Finland, and the United Kingdom. Our matching contributions for all defined contribution plans were $1.8 million and $1.3 million for the three months ended June 30, 2021 and 2020, respectively and $3.8 million and $2.8 million for the six months ended June 30, 2021 and 2020, respectively.

Segment Data

Segment Data	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Segment Data	14. Segment Data Our operations are comprised of two reportable segments: the manufacture and sale of CEDs, batteries, accessories, extended warranties and other products and services (the “TASER” segment); and the software and sensors business, which includes the sale of devices, wearables, applications, cloud and mobile products, and services (collectively, the “Software and Sensors” segment). In both segments, we report sales of products and services. Service revenue in both segments includes sales related to Axon Evidence. In the Software and Sensors segment, service revenue also includes other recurring cloud-hosted software revenue and related professional services. Collectively, this revenue is sometimes referred to as "Axon Cloud revenue." Our Chief Executive Officer, who is the CODM, is not provided asset information or sales, general, and administrative expense by segment. Information relative to our reportable segments was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2021 ​ Three Months Ended June 30, 2020 ​ ​ ​ ​ ​ Software and ​ ​ ​ ​ ​ ​ ​ Software and ​ ​ ​ ​ TASER Sensors Total TASER Sensors Total Net sales from products ​ $ 110,637 ​ $ 45,790 ​ $ 156,427 ​ $ 69,877 ​ $ 28,878 ​ $ 98,755 Net sales from services ​ 1,891 ​ 60,477 ​ 62,368 ​ 613 ​ 41,891 ​ 42,504 Net sales ​ 112,528 ​ 106,267 ​ 218,795 ​ 70,490 ​ 70,769 ​ 141,259 Cost of product sales ​ 37,701 ​ 27,600 ​ 65,301 ​ 27,242 ​ 16,583 ​ 43,825 Cost of service sales ​ 145 ​ 15,420 ​ 15,565 ​ — ​ 9,257 ​ 9,257 Cost of sales ​ 37,846 ​ 43,020 ​ 80,866 ​ 27,242 ​ 25,840 ​ 53,082 Gross margin ​ $ 74,682 ​ $ 63,247 ​ $ 137,929 ​ $ 43,248 ​ $ 44,929 ​ $ 88,177 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ $ 12,313 ​ $ 41,639 ​ $ 53,952 ​ $ 3,762 ​ $ 25,798 ​ $ 29,560 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ Six Months Ended June 30, 2020 ​ ​ ​ ​ ​ Software and ​ ​ ​ ​ ​ ​ ​ Software and ​ ​ ​ ​ TASER Sensors Total TASER Sensors Total Net sales from products ​ $ 207,939 ​ ​ 89,374 ​ $ 297,313 ​ $ 145,052 ​ ​ 60,991 ​ $ 206,043 Net sales from services ​ 3,588 ​ 112,913 ​ 116,501 ​ 1,333 ​ 81,045 ​ 82,378 Net sales ​ 211,527 ​ 202,287 ​ 413,814 ​ 146,385 ​ 142,036 ​ 288,421 Cost of product sales ​ 70,646 ​ 53,271 ​ 123,917 ​ 57,490 ​ 35,219 ​ 92,709 Cost of service sales ​ 145 ​ 28,470 ​ 28,615 ​ — ​ 18,927 ​ 18,927 Cost of sales ​ 70,791 ​ 81,741 ​ 152,532 ​ 57,490 ​ 54,146 ​ 111,636 Gross margin ​ $ 140,736 ​ $ 120,546 ​ $ 261,282 ​ $ 88,895 ​ $ 87,890 ​ $ 176,785 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ $ 21,556 ​ $ 79,414 ​ $ 100,970 ​ $ 6,794 ​ $ 49,147 ​ $ 55,941 ​

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC. Certain information related to our organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in our annual consolidated financial statements for the year ended December 31, 2020, as filed on Form 10-K, with the exception of our adoption of certain accounting pronouncements which we describe below. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with our Form 10-K for the year ended December 31, 2020. The results of operations for the three months and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include: ● product warranty reserves, ● inventory valuation, ● revenue recognition, ● reserve for expected credit loss, ● valuation of goodwill, intangible and long-lived assets, ● recognition, measurement and valuation of current and deferred income taxes, ● stock-based compensation, and ● recognition and measurement of contingencies and accrued litigation expense. ​ Actual results could differ materially from those estimates.
Segment Information	Segment Information Our operations are comprised of two reportable segments: the manufacture and sale of conducted electrical devices ("CEDs"), batteries, accessories, extended warranties and other products and services (the “TASER” segment); and the development, manufacture, and sale of software and sensors, which includes the sale of devices, wearables, applications, cloud and mobile products, and services (collectively, the “Software and Sensors” segment). In both segments, we report sales of products and services. Service revenue in both segments includes sales related to Axon Evidence. In the Software and Sensors segment, service revenue also includes other recurring cloud-hosted software revenue and related professional services. Collectively, this revenue is sometimes referred to as "Axon Cloud revenue." Reportable segments are determined based on discrete financial information reviewed by our Chief Executive Officer who is our chief operating decision maker ("CODM"). We organize and review operations based on products and services, and currently there are no operating segments that are aggregated. We perform an analysis of our reportable segments at least annually. Additional information related to our business segments is summarized in Note 14.
Geographic Information and Major Customers / Suppliers	Geographic Information and Major Customers / Suppliers For the three and six months ended June 30, 2021, no individual country outside the U.S. represented more than 10% of total net sales. Individual sales transactions in the international market are generally larger and occur more intermittently than in the domestic market due to the profile of our customers. For the three and six months ended June 30, 2021, no customer represented more than 10% of total net sales. At June 30, 2021 and December 31, 2020, no customer represented more than 10% of the aggregate balance of accounts and notes receivable and contract assets. We currently purchase both off the shelf and custom components, including, but not limited to, finished circuit boards, injection-molded plastic components, small machined parts, custom cartridge components, electronic components, and off the shelf sub-assemblies from suppliers located in the U.S., Canada, China, Israel, Republic of Korea, Mexico, Sri Lanka, and Taiwan. Although we currently obtain many of these components from single source suppliers, we own the injection molded component tooling, most of the designs, and the test fixtures used in their production for all custom components. As a result, we believe we could obtain alternative suppliers in most cases without incurring significant production delays. We also strategically hold safety stock levels on custom components to further reduce this risk. For off the shelf components, we believe that in most cases there are readily available alternative suppliers who can consistently meet our needs for these components. We acquire most of our components on a purchase order basis and do not have any significant long-term contracts with component suppliers.
Income per Common Share	Income per Common Share Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution from outstanding stock options and unvested restricted stock units. The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2021 2020 2021 2020 Numerator for basic and diluted earnings per share: ​ ​ ​ ​ Net loss ​ $ (47,117) ​ $ (30,759) ​ $ (95,034) ​ $ (26,685) Denominator: ​ ​ ​ ​ ​ Weighted average shares outstanding ​ 65,166 ​ 60,346 ​ 64,604 ​ 59,977 Dilutive effect of stock-based awards ​ — ​ — ​ — ​ — Diluted weighted average shares outstanding ​ 65,166 ​ 60,346 ​ 64,604 ​ 59,977 Anti-dilutive stock-based awards excluded ​ 10,537 ​ 12,773 ​ 8,950 ​ 12,866 Net loss per common share: ​ ​ ​ ​ ​ Basic ​ $ (0.72) ​ $ (0.51) ​ $ (1.47) ​ $ (0.44) Diluted ​ $ (0.72) ​ $ (0.51) ​ $ (1.47) ​ $ (0.44)
Standard Warranties	Standard Warranties We warranty our CEDs, Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will repair or replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold when revenue is recorded for the related product. Future warranty costs are estimated based on historical data related to warranty claims and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure or other issue that could result in larger than anticipated warranty claims from customers. The warranty reserve is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. The warranty reserve is included in accrued liabilities on the accompanying condensed consolidated balance sheets. Changes in our estimated product warranty liabilities were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 ​ 2020 Balance, beginning of period ​ $ 769 ​ $ 1,476 Utilization of reserve ​ (481) ​ (350) Warranty expense (benefit) ​ 613 ​ (114) Balance, end of period ​ $ 901 ​ $ 1,012
Fair Value Measurements and Financial Instruments	Fair Value Measurements and Financial Instruments We use the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: ● Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured. ● Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques. ● Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect our own assumptions about inputs that market participants would use in pricing an asset or liability. We have cash equivalents and investments, which at June 30, 2021 and December 31, 2020 were comprised of money market funds, certificates of deposit, commercial paper, corporate bonds, municipal bonds, U.S. Government agency bonds, and U.S. Treasury bills. Also included in cash equivalents and investments at December 31, 2020 were U.S. Treasury repurchase agreements and U.S. Treasury inflation-protected securities. See additional disclosure regarding the fair value of our cash equivalents and investments in Note 3. Included in the balance of other assets as of June 30, 2021 and December 31, 2020 was $5.1 million and $4.7 million, respectively, related to corporate-owned life insurance policies which are used to fund our deferred compensation plan. We determine the fair value of insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique. ​ We have strategic investments in three unconsolidated affiliates, which are included within other assets. The estimated fair value of the investments was determined based on Level 3 inputs. As of June 30, 2021, management estimated that the fair value of the investments equaled the carrying value. ​ Our financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the balance sheet.
Restricted cash	Restricted Cash Restricted cash balances as of June 30, 2021 and December 31, 2020 included $0.1 million primarily related to funds held in an international bank account for a country in which we are required to maintain a minimum balance to operate. Approximately half of the balance was included in prepaid expenses and other current assets on our condensed consolidated balance sheets, with the remainder included in other assets.
Valuation of Goodwill, Intangibles and Long-lived Assets	Valuation of Goodwill, Intangibles and Long-lived Assets We evaluate whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets, excluding goodwill and intangible assets with indefinite useful lives, may warrant revision or that the remaining balance of these assets may not be recoverable. Such circumstances could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, we estimate the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows. We do not amortize goodwill and intangible assets with indefinite useful lives; rather such assets are required to be tested for impairment at least annually or sooner whenever events or changes in circumstances indicate that the assets may be impaired. We perform our annual goodwill and intangible asset impairment tests in the fourth quarter of each year.
Recently Issued Accounting Guidance	Recently Issued Accounting Guidance Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Simplifying the Accounting for Income Taxes. Adoption of this ASU on January 1, 2021 did not have a material impact on our consolidated financial statements. ​ In January 2020, the FASB issued ASU No. 2020-01, Investments – Equity Securities (Topic 321), Investments – Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) – Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815 (a Consensus of the Emerging Issues Task Force). The guidance clarifies the interaction between ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities and the ASU on equity method investments. ASU 2016-01 provides companies with an alternative to measure certain equity securities without a readily determinable fair value at cost, minus impairment, if any, unless an observable transaction for an identical or similar security occurs. ASU 2020-01 clarifies that for purposes of applying the Topic 321 measurement alternative, an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting under Topic 323, immediately before applying or upon discontinuing the equity method. In addition, the new ASU provides direction that a company should not consider whether the underlying securities would be accounted for under the equity method or the fair value option when it is determining the accounting for certain forward contracts and purchased options, upon either settlement or exercise. Adoption of this ASU on January 1, 2021 did not have a material impact on our consolidated financial statements.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications are not material and had no effect on the reported results of operations.

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Weighted Average Number of Shares Outstanding and Income Per Share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2021 2020 2021 2020 Numerator for basic and diluted earnings per share: ​ ​ ​ ​ Net loss ​ $ (47,117) ​ $ (30,759) ​ $ (95,034) ​ $ (26,685) Denominator: ​ ​ ​ ​ ​ Weighted average shares outstanding ​ 65,166 ​ 60,346 ​ 64,604 ​ 59,977 Dilutive effect of stock-based awards ​ — ​ — ​ — ​ — Diluted weighted average shares outstanding ​ 65,166 ​ 60,346 ​ 64,604 ​ 59,977 Anti-dilutive stock-based awards excluded ​ 10,537 ​ 12,773 ​ 8,950 ​ 12,866 Net loss per common share: ​ ​ ​ ​ ​ Basic ​ $ (0.72) ​ $ (0.51) ​ $ (1.47) ​ $ (0.44) Diluted ​ $ (0.72) ​ $ (0.51) ​ $ (1.47) ​ $ (0.44)
Summary of Changes in Estimated Product Warranty Liabilities	Changes in our estimated product warranty liabilities were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, ​ 2021 ​ 2020 Balance, beginning of period ​ $ 769 ​ $ 1,476 Utilization of reserve ​ (481) ​ (350) Warranty expense (benefit) ​ 613 ​ (114) Balance, end of period ​ $ 901 ​ $ 1,012

Revenues (Tables)

Revenues (Tables)	6 Months Ended
	Jun. 30, 2021
Revenues
Summary of Revenue by Product and Service Offering and Geography	The following tables present our revenues by primary product and service offering (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2021 ​ Three Months Ended June 30, 2020 ​ ​ ​ Software and ​ ​ ​ ​ Software and ​ ​ ​ ​ TASER ​ Sensors ​ Total ​ TASER ​ Sensors ​ Total TASER 7 ​ $ 28,128 ​ ​ — ​ $ 28,128 ​ $ 11,588 ​ $ — ​ $ 11,588 TASER X26P ​ 9,569 ​ ​ — ​ 9,569 ​ 9,511 ​ — ​ 9,511 TASER X2 ​ 16,145 ​ ​ — ​ 16,145 ​ 16,832 ​ — ​ 16,832 TASER Pulse ​ 1,701 ​ ​ — ​ 1,701 ​ 2,193 ​ — ​ 2,193 Cartridges ​ 46,678 ​ ​ — ​ 46,678 ​ 23,772 ​ — ​ 23,772 Axon Body ​ — ​ ​ 19,927 ​ 19,927 ​ — ​ 11,844 ​ 11,844 Axon Flex ​ — ​ ​ 1,088 ​ 1,088 ​ — ​ 680 ​ 680 Axon Fleet ​ — ​ ​ 5,247 ​ 5,247 ​ — ​ 4,098 ​ 4,098 Axon Dock ​ — ​ ​ 5,509 ​ 5,509 ​ — ​ 4,055 ​ 4,055 Axon Evidence and cloud services ​ 1,702 ​ ​ 60,367 ​ 62,069 ​ 586 ​ 41,891 ​ 42,477 Extended warranties ​ 5,857 ​ ​ 8,149 ​ 14,006 ​ 5,098 ​ 5,735 ​ 10,833 Other ​ 2,748 ​ ​ 5,980 ​ 8,728 ​ 910 ​ 2,466 ​ 3,376 Total ​ $ 112,528 ​ $ 106,267 ​ $ 218,795 ​ $ 70,490 ​ $ 70,769 ​ $ 141,259 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ Six Months Ended June 30, 2020 ​ ​ ​ Software and ​ ​ ​ ​ Software and ​ ​ ​ ​ TASER ​ Sensors ​ Total ​ TASER ​ Sensors ​ Total TASER 7 ​ $ 62,119 ​ ​ — ​ $ 62,119 ​ $ 26,914 ​ $ — ​ $ 26,914 TASER X26P ​ 19,532 ​ ​ — ​ 19,532 ​ 20,572 ​ — ​ 20,572 TASER X2 ​ 28,923 ​ ​ — ​ 28,923 ​ 30,907 ​ — ​ 30,907 TASER Pulse ​ 3,906 ​ ​ — ​ 3,906 ​ 3,393 ​ — ​ 3,393 Cartridges ​ 77,096 ​ ​ — ​ 77,096 ​ 50,397 ​ — ​ 50,397 Axon Body ​ — ​ ​ 39,683 ​ 39,683 ​ — ​ 24,667 ​ 24,667 Axon Flex ​ — ​ ​ 1,993 ​ 1,993 ​ — ​ 1,863 ​ 1,863 Axon Fleet ​ — ​ ​ 9,010 ​ 9,010 ​ — ​ 8,873 ​ 8,873 Axon Dock ​ — ​ ​ 12,429 ​ 12,429 ​ — ​ 9,006 ​ 9,006 Axon Evidence and cloud services ​ 3,098 ​ ​ 112,661 ​ 115,759 ​ 1,084 ​ 81,045 ​ 82,129 Extended warranties ​ 11,503 ​ ​ 15,649 ​ 27,152 ​ 10,075 ​ 11,193 ​ 21,268 Other ​ 5,350 ​ ​ 10,862 ​ 16,212 ​ 3,043 ​ 5,389 ​ 8,432 Total ​ $ 211,527 ​ $ 202,287 ​ $ 413,814 ​ $ 146,385 ​ $ 142,036 ​ $ 288,421 ​ ​ The following table presents our revenues disaggregated by geography (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ ​ Six Months Ended June 30, ​ ​ 2021 ​ ​ 2020 ​ ​ 2021 ​ 2020 United States $ 164,908 75 % ​ $ 107,547 76 % ​ $ 325,294 79 % $ 225,010 78 % Other countries ​ 53,887 25 ​ ​ 33,712 24 ​ ​ 88,520 21 ​ 63,411 22 ​ Total ​ $ 218,795 100 % ​ $ 141,259 100 % ​ $ 413,814 100 % $ 288,421 100 %
Contract with Customer, Assets and Liabilities	The following table presents our contract assets, contract liabilities and certain information related to these balances as of and for the six months ended June 30, 2021 (in thousands): ​ ​ ​ ​ ​ ​ June 30, 2021 Contract assets, net ​ $ 118,252 Contract liabilities (deferred revenue) ​ 300,724 Revenue recognized in the period from: ​ Amounts included in contract liabilities at the beginning of the period ​ 111,375 ​ Contract liabilities (deferred revenue) consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ December 31, 2020 ​ Current Long-Term Total Current Long-Term Total Warranty: ​ ​ ​ ​ ​ ​ TASER ​ $ 12,467 ​ $ 16,937 ​ $ 29,404 ​ $ 11,635 ​ $ 16,953 ​ $ 28,588 Software and Sensors ​ 14,606 ​ 5,493 ​ 20,099 ​ 13,926 ​ 5,025 ​ 18,951 ​ ​ 27,073 ​ 22,430 ​ 49,503 ​ 25,561 ​ 21,978 ​ 47,539 Hardware: ​ ​ ​ ​ ​ ​ TASER ​ 22,408 ​ 11,498 ​ 33,906 ​ 16,314 ​ 14,304 ​ 30,618 Software and Sensors ​ 30,033 ​ 50,081 ​ 80,114 ​ 25,181 ​ 50,981 ​ 76,162 ​ ​ 52,441 ​ 61,579 ​ 114,020 ​ 41,495 ​ 65,285 ​ 106,780 Services: ​ ​ ​ ​ ​ ​ TASER ​ 1,200 ​ 3,455 ​ 4,655 ​ 996 ​ 1,554 ​ 2,550 Software and Sensors ​ 106,195 ​ 26,351 ​ 132,546 ​ 95,907 ​ 22,405 ​ 118,312 ​ ​ ​ 107,395 ​ ​ 29,806 ​ ​ 137,201 ​ ​ 96,903 ​ ​ 23,959 ​ ​ 120,862 Total ​ $ 186,909 ​ $ 113,815 ​ $ 300,724 ​ $ 163,959 ​ $ 111,222 ​ $ 275,181 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 ​ December 31, 2020 ​ Current Long-Term Total Current Long-Term Total TASER ​ $ 36,075 ​ $ 31,890 ​ $ 67,965 ​ $ 28,945 ​ $ 32,811 ​ $ 61,756 Software and Sensors ​ 150,834 ​ 81,925 ​ 232,759 ​ 135,014 ​ 78,411 ​ 213,425 Total ​ $ 186,909 ​ $ 113,815 ​ $ 300,724 ​ $ 163,959 ​ $ 111,222 ​ $ 275,181

Cash, Cash Equivalents and In_2

Cash, Cash Equivalents and Investments (Tables)	6 Months Ended
	Jun. 30, 2021
Cash, Cash Equivalents and Investments
Summary of Cash, Cash Equivalents and Held-to-Maturity Investments by Type	The following tables summarize our cash, cash equivalents, and held-to-maturity investments at June 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2021 ​ ​ ​ Gross Gross ​ ​ Cash and ​ ​ ​ ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ ​ ​ ​ ​ Cash ​ Short-Term ​ Long-Term ​ ​ Cost ​ Gains ​ Losses ​ Fair Value ​ ​ Equivalents ​ Investments ​ Investments Cash ​ $ 199,426 ​ $ — ​ $ — ​ $ 199,426 ​ ​ $ 199,426 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1: ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ 48,052 ​ — ​ — ​ 48,052 ​ ​ 48,052 ​ — ​ — Agency bonds ​ 73,669 ​ 74 ​ — ​ 73,743 ​ ​ 5,500 ​ 60,169 ​ 8,000 Treasury bills ​ ​ 96,795 ​ ​ 2 ​ ​ (1) ​ ​ 96,796 ​ ​ ​ 12,600 ​ ​ 84,195 ​ ​ — Subtotal ​ 218,516 ​ 76 ​ (1) ​ 218,591 ​ ​ 66,152 ​ 144,364 ​ 8,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 2: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ State and municipal obligations ​ 101,610 ​ ​ 14 ​ ​ (27) ​ ​ 101,597 ​ ​ ​ 801 ​ ​ 87,596 ​ ​ 13,213 Certificates of deposit ​ ​ 500 ​ ​ — ​ ​ — ​ ​ 500 ​ ​ ​ — ​ ​ 500 ​ ​ — Corporate bonds ​ ​ 150,082 ​ ​ 105 ​ ​ (32) ​ ​ 150,155 ​ ​ ​ — ​ ​ 122,607 ​ ​ 27,475 Commercial paper ​ 33,983 ​ ​ — ​ ​ — ​ ​ 33,983 ​ ​ ​ — ​ ​ 33,983 ​ ​ — Subtotal ​ 286,175 ​ ​ 119 ​ ​ (59) ​ ​ 286,235 ​ ​ ​ 801 ​ ​ 244,686 ​ ​ 40,688 Total ​ $ 704,117 ​ $ 195 ​ $ (60) ​ $ 704,252 ​ ​ ​ 266,379 ​ ​ 389,050 ​ ​ 48,688 Expected credit loss reserve ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (7) ​ ​ (155) ​ ​ (19) Total, net of reserve for expected credit losses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 266,372 ​ $ 388,895 ​ $ 48,669 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 ​ ​ ​ Gross Gross ​ ​ Cash and ​ ​ ​ ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ ​ ​ ​ ​ Cash ​ Short-Term ​ Long-Term ​ ​ Cost ​ Gains ​ Losses ​ Fair Value ​ ​ Equivalents ​ Investments ​ Investments Cash ​ $ 116,107 ​ $ — ​ $ — ​ $ 116,107 ​ ​ $ 116,107 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1: ​ ​ ​ ​ ​ ​ ​ ​ Money market funds ​ 23,611 ​ — ​ — ​ 23,611 ​ ​ 23,611 ​ — ​ — Agency bonds ​ 63,794 ​ 122 ​ — ​ 63,916 ​ ​ — ​ 23,794 ​ 40,000 Treasury Bills ​ ​ 96,384 ​ ​ 6 ​ ​ — ​ ​ 96,390 ​ ​ ​ ​ ​ ​ 96,384 ​ ​ ​ Subtotal ​ 183,789 ​ 128 ​ — ​ 183,917 ​ ​ 23,611 ​ 120,178 ​ 40,000 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 2: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ State and municipal obligations ​ ​ 77,130 ​ ​ 25 ​ ​ (28) ​ ​ 77,127 ​ ​ ​ — ​ ​ 66,519 ​ ​ 10,611 Certificates of deposit ​ ​ 500 ​ ​ — ​ ​ — ​ ​ 500 ​ ​ ​ — ​ ​ 500 ​ ​ — Corporate bonds ​ ​ 212,825 ​ ​ 232 ​ ​ (100) ​ ​ 212,957 ​ ​ ​ 2,525 ​ ​ 170,205 ​ ​ 40,095 U.S. Treasury repurchase agreements ​ ​ 13,200 ​ ​ — ​ ​ — ​ ​ 13,200 ​ ​ ​ 13,200 ​ ​ — ​ ​ — Treasury inflation-protected securities ​ ​ 3,291 ​ ​ 16 ​ ​ — ​ ​ 3,307 ​ ​ ​ — ​ ​ 3,291 ​ ​ ​ Commercial paper ​ ​ 45,974 ​ ​ — ​ ​ — ​ ​ 45,974 ​ ​ ​ ​ ​ ​ 45,974 ​ ​ — Subtotal ​ ​ 352,920 ​ ​ 273 ​ ​ (128) ​ ​ 353,065 ​ ​ ​ 15,725 ​ ​ 286,489 ​ ​ 50,706 Total ​ $ 652,816 ​ $ 401 ​ $ (128) ​ $ 653,089 ​ ​ ​ 155,443 ​ ​ 406,667 ​ ​ 90,706 Expected credit loss reserve ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (3) ​ ​ (142) ​ ​ (25) Total, net of reserve for expected credit losses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 155,440 ​ $ 406,525 ​ $ 90,681

Expected Credit Losses (Tables)

Expected Credit Losses (Tables)	6 Months Ended
	Jun. 30, 2021
Expected Credit Losses
Schedule of roll-forward of allowance for credit losses	The following table provides a roll-forward of the allowance for expected credit losses that is deducted from the amortized cost basis of accounts receivable, notes receivable, and contract assets to present the net amount expected to be collected (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ ​ ​ United States ​ ​ Other countries ​ ​ Total Balance, beginning of period ​ $ 2,902 ​ $ 474 ​ $ 3,376 Provision for expected credit losses ​ ​ 256 ​ ​ (130) ​ ​ 126 Amounts written off charged against the allowance ​ ​ (54) ​ ​ - ​ ​ (54) Other, including dispositions and foreign currency translation ​ 78 ​ (9) ​ 69 Balance, end of period ​ $ 3,182 ​ $ 335 ​ $ 3,517
Schedule of allowance for expected credit losses for each type of customer receivable	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2021 ​ 2020 Accounts receivable and notes receivable, current ​ $ 1,973 ​ $ 2,105 Contract assets, net ​ 1,186 ​ 794 Long-term notes receivable, net of current portion ​ 358 ​ 477 Total allowance for expected credit losses on customer receivables ​ $ 3,517 ​ $ 3,376

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Inventory	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 December 31, 2020 Raw materials ​ $ 35,935 ​ $ 39,194 Finished goods ​ 55,804 ​ 50,764 Total inventory ​ $ 91,739 ​ $ 89,958

Strategic Investments (Tables)

Strategic Investments (Tables)	6 Months Ended
	Jun. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Schedule of Roll-Forward of Strategic Investments	The following tables provides a roll-forward of the balance of strategic investments (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ ​ Strategic investments ​ Warrants for strategic investment ​ Total Balance, beginning of period ​ $ 9,500 ​ $ 2,211 ​ $ 11,711 Investments ​ ​ 20,500 ​ ​ - ​ ​ 20,500 Observable price changes ​ ​ 40,321 ​ ​ 534 ​ ​ 40,855 Sales ​ ​ (14,546) ​ ​ - ​ ​ (14,546) Balance, end of period ​ $ 55,775 ​ $ 2,745 ​ $ 58,520 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Inception to date ​ ​ Strategic investments ​ Warrants for strategic investment ​ Total Investments ​ $ 27,568 ​ $ 2,588 ​ $ 30,156 Observable price changes ​ ​ 42,753 ​ ​ 157 ​ ​ 42,910 Sales ​ ​ (14,546) ​ ​ - ​ ​ (14,546) Balance, end of period ​ $ 55,775 ​ $ 2,745 ​ $ 58,520

Other Long-Term Assets (Tables)

Other Long-Term Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Long-Term Assets	Other long-term assets consisted of the following at June 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 December 31, 2020 Cash surrender value of corporate-owned life insurance policies ​ $ 5,055 ​ $ 4,654 Deferred commissions (1) ​ 36,489 ​ 32,455 Restricted cash ​ 60 ​ 62 Operating lease assets ​ 26,885 ​ 22,308 Prepaid expenses, deposits and other ​ 15,755 ​ 8,727 Total other long-term assets ​ $ 84,244 ​ $ 68,206 (1) Represents the incremental costs of obtaining contracts with customers, which consist primarily of sales commissions. These costs are ascribed to or allocated to the underlying performance obligations in the contracts and amortized consistent with the recognition timing of the revenue for the underlying performance obligations.

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
Schedule of Accrued liabilities	Accrued liabilities consisted of the following at June 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2021 December 31, 2020 Accrued salaries, benefits and bonus ​ $ 39,487 ​ $ 36,892 Accrued professional, consulting and lobbying fees ​ 1,201 ​ 3,055 Accrued warranty expense ​ 901 ​ 769 Accrued income and other taxes ​ ​ 3,780 ​ ​ 3,848 Accrued inventory in transit ​ 10,979 ​ 4,597 Other accrued expenses ​ 10,560 ​ 10,682 Accrued liabilities ​ $ 66,908 ​ $ 59,843

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Equity Compensation Goals	​ ​ ​ ​ ​ Eight Separate Adjusted EBITDA (CEO Eight Separate Revenue Goals (1) ​ Performance Award) Goals (in thousands) ​ (in thousands) Goal #1, $710,058 Goal #9, $125,000 Goal #2, $860,058 Goal #10, $155,000 Goal #3, $1,010,058 Goal #11, $175,000 Goal #4, $1,210,058 Goal #12, $190,000 Goal #5, $1,410,058 Goal #13, $200,000 Goal #6, $1,610,058 Goal #14, $210,000 Goal #7, $1,810,058 Goal #15, $220,000 Goal #8, $2,010,058 Goal #16, $230,000 (1) In connection with the business acquisition that was completed during the three months ended June 30, 2018, the revenue goals were adjusted for the acquiree’s Target Revenue, as defined in the CEO Performance Award agreement.
Summary of Restricted Stock Unit Activity	The following table summarizes RSU activity for the six months ended June 30, 2021 (number of units and aggregate intrinsic value in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Weighted Average Aggregate ​ ​ Units ​ Grant-Date Fair Value ​ Intrinsic Value Units outstanding, beginning of year 1,107 ​ $ 76.10 ​ Granted 98 ​ 149.92 ​ Released (276) ​ 51.65 ​ Forfeited (64) ​ 98.43 ​ Units outstanding, end of period 865 ​ 90.59 ​ $ 152,892
Summary of Performance Stock Unit Activity	The following table summarizes PSU activity, inclusive of XSUs, for the six months ended June 30, 2021 (number of units and aggregate intrinsic value in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of Weighted Average Aggregate ​ ​ Units ​ Grant-Date Fair Value ​ Intrinsic Value Units outstanding, beginning of year 5,618 ​ $ 35.71 ​ Granted 225 ​ 50.00 ​ Released (1,696) ​ 41.20 ​ Forfeited (60) ​ 35.80 ​ Units outstanding, end of period 4,087 ​ 34.22 ​ $ 722,593
Summary of the Company's Stock Options Activity	The following table summarizes stock option activity for the six months ended June 30, 2021 (number of units and aggregate intrinsic value in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ Weighted ​ Average ​ ​ ​ ​ ​ Number ​ Average ​ Remaining ​ ​ ​ ​ ​ of ​ Exercise ​ Contractual ​ Aggregate ​ ​ Options ​ Price ​ Life (years) ​ Intrinsic Value Options outstanding, beginning of year 6,366 ​ $ 28.58 ​ Granted — ​ ​ — ​ Exercised — ​ ​ — ​ Expired / terminated — ​ ​ — ​ Options outstanding, end of period 6,366 ​ 28.58 6.66 ​ $ 943,547 Options exercisable, end of period 4,243 ​ 28.58 6.66 ​ 629,031
Reported Share-Based Compensation	The following table summarizes the composition of stock-based compensation expense for the three and six months ended June 30, 2021 and 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2021 2020 2021 2020 Cost of products sold and services delivered ​ $ 1,838 ​ $ 836 ​ $ 3,327 ​ $ 1,426 Sales, general and administrative expenses ​ 114,089 ​ 26,766 ​ 185,104 ​ 41,736 Research and development expenses ​ 21,622 ​ 6,233 ​ 38,728 ​ 10,868 Total stock-based compensation expense ​ $ 137,549 ​ $ 33,835 ​ $ 227,159 ​ $ 54,030

Segment Data (Tables)

Segment Data (Tables)	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
Summary of Operational Information Relative to the Company's Reportable Segments	Information relative to our reportable segments was as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2021 ​ Three Months Ended June 30, 2020 ​ ​ ​ ​ ​ Software and ​ ​ ​ ​ ​ ​ ​ Software and ​ ​ ​ ​ TASER Sensors Total TASER Sensors Total Net sales from products ​ $ 110,637 ​ $ 45,790 ​ $ 156,427 ​ $ 69,877 ​ $ 28,878 ​ $ 98,755 Net sales from services ​ 1,891 ​ 60,477 ​ 62,368 ​ 613 ​ 41,891 ​ 42,504 Net sales ​ 112,528 ​ 106,267 ​ 218,795 ​ 70,490 ​ 70,769 ​ 141,259 Cost of product sales ​ 37,701 ​ 27,600 ​ 65,301 ​ 27,242 ​ 16,583 ​ 43,825 Cost of service sales ​ 145 ​ 15,420 ​ 15,565 ​ — ​ 9,257 ​ 9,257 Cost of sales ​ 37,846 ​ 43,020 ​ 80,866 ​ 27,242 ​ 25,840 ​ 53,082 Gross margin ​ $ 74,682 ​ $ 63,247 ​ $ 137,929 ​ $ 43,248 ​ $ 44,929 ​ $ 88,177 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ $ 12,313 ​ $ 41,639 ​ $ 53,952 ​ $ 3,762 ​ $ 25,798 ​ $ 29,560 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ Six Months Ended June 30, 2020 ​ ​ ​ ​ ​ Software and ​ ​ ​ ​ ​ ​ ​ Software and ​ ​ ​ ​ TASER Sensors Total TASER Sensors Total Net sales from products ​ $ 207,939 ​ ​ 89,374 ​ $ 297,313 ​ $ 145,052 ​ ​ 60,991 ​ $ 206,043 Net sales from services ​ 3,588 ​ 112,913 ​ 116,501 ​ 1,333 ​ 81,045 ​ 82,378 Net sales ​ 211,527 ​ 202,287 ​ 413,814 ​ 146,385 ​ 142,036 ​ 288,421 Cost of product sales ​ 70,646 ​ 53,271 ​ 123,917 ​ 57,490 ​ 35,219 ​ 92,709 Cost of service sales ​ 145 ​ 28,470 ​ 28,615 ​ — ​ 18,927 ​ 18,927 Cost of sales ​ 70,791 ​ 81,741 ​ 152,532 ​ 57,490 ​ 54,146 ​ 111,636 Gross margin ​ $ 140,736 ​ $ 120,546 ​ $ 261,282 ​ $ 88,895 ​ $ 87,890 ​ $ 176,785 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ $ 21,556 ​ $ 79,414 ​ $ 100,970 ​ $ 6,794 ​ $ 49,147 ​ $ 55,941

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)customercountry	Jun. 30, 2021USD ($)customeritemsegmentcountry	Dec. 31, 2020USD ($)customer
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of reportable segments | segment		2
Warranty period		1 year
Cash surrender value of corporate-owned life insurance policies	$ 5,055	$ 5,055	$ 4,654
Investments in number of unconsolidated affiliates | item		3
Restricted cash balance	60	$ 60	62
Prepaid Expenses and Other Current Assets
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Restricted cash balance	$ 100	$ 100	$ 100
Net Sales | Geographic Concentration Risk
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of countries outside the U.S. representing more than 10% of total net sales | country	0	0
Net Sales | Customer Concentration Risk
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of major customers | customer	0	0
Accounts and notes receivable and contract assets | Customer Concentration Risk
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of major customers | customer		0	0

Organization and Summary of S_5

Organization and Summary of Significant Accounting Policies - Weighted Average Number of Shares Outstanding and Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator for basic and diluted earnings per share:
Net loss	$ (47,117)	$ (47,917)	$ (30,759)	$ 4,074	$ (95,034)	$ (26,685)
Denominator:
Weighted average shares outstanding basic (in shares)	65,166		60,346		64,604	59,977
Diluted weighted average shares outstanding (in shares)	65,166		60,346		64,604	59,977
Anti-dilutive stock-based awards excluded (in shares)	10,537		12,773		8,950	12,866
Net loss per common share:
Basic (in dollars per share)	$ (0.72)		$ (0.51)		$ (1.47)	$ (0.44)
Diluted (in dollars per share)	$ (0.72)		$ (0.51)		$ (1.47)	$ (0.44)

Organization and Summary of S_6

Organization and Summary of Significant Accounting Policies - Summary of Changes in Estimated Product Warranty Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Movement in Standard and Extended Product Warranty
Balance, beginning of period	$ 769	$ 1,476
Utilization of reserve	(481)	(350)
Warranty expense (benefit)	613	(114)
Balance, end of period	$ 901	$ 1,012

Revenues - Revenues By Products

Revenues - Revenues By Products And Service Offerings (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	$ 218,795	$ 141,259	$ 413,814	$ 288,421
TASER 7
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	28,128	11,588	62,119	26,914
TASER X26P
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	9,569	9,511	19,532	20,572
TASER X2
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	16,145	16,832	28,923	30,907
TASER Pulse
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	1,701	2,193	3,906	3,393
Cartridges
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	46,678	23,772	77,096	50,397
Axon Body
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	19,927	11,844	39,683	24,667
Axon Flex
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	1,088	680	1,993	1,863
Axon Fleet
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	5,247	4,098	9,010	8,873
Axon Dock
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	5,509	4,055	12,429	9,006
Axon Evidence and cloud services
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	62,069	42,477	115,759	82,129
Extended warranties
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	14,006	10,833	27,152	21,268
Other
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	8,728	3,376	16,212	8,432
TASER
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	112,528	70,490	211,527	146,385
TASER | TASER 7
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	28,128	11,588	62,119	26,914
TASER | TASER X26P
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	9,569	9,511	19,532	20,572
TASER | TASER X2
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	16,145	16,832	28,923	30,907
TASER | TASER Pulse
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	1,701	2,193	3,906	3,393
TASER | Cartridges
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	46,678	23,772	77,096	50,397
TASER | Axon Body
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers		0
TASER | Axon Flex
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers		0
TASER | Axon Fleet
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers		0
TASER | Axon Dock
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers		0
TASER | Axon Evidence and cloud services
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	1,702	586	3,098	1,084
TASER | Extended warranties
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	5,857	5,098	11,503	10,075
TASER | Other
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	2,748	910	5,350	3,043
Software and Sensors
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	106,267	70,769	202,287	142,036
Software and Sensors | TASER 7
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers		0
Software and Sensors | TASER X26P
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers		0
Software and Sensors | TASER X2
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers		0
Software and Sensors | TASER Pulse
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers		0
Software and Sensors | Cartridges
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers		0
Software and Sensors | Axon Body
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	19,927	11,844	39,683	24,667
Software and Sensors | Axon Flex
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	1,088	680	1,993	1,863
Software and Sensors | Axon Fleet
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	5,247	4,098	9,010	8,873
Software and Sensors | Axon Dock
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	5,509	4,055	12,429	9,006
Software and Sensors | Axon Evidence and cloud services
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	60,367	41,891	112,661	81,045
Software and Sensors | Extended warranties
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	8,149	5,735	15,649	11,193
Software and Sensors | Other
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Revenue from contract with customers	$ 5,980	$ 2,466	$ 10,862	$ 5,389

Revenues - Revenues By Geograph

Revenues - Revenues By Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	$ 218,795	$ 141,259	$ 413,814	$ 288,421
United States
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	164,908	107,547	325,294	225,010
Other countries
Disaggregation of Revenue [Line Items]
Revenue from contract with customers	$ 53,887	$ 33,712	$ 88,520	$ 63,411
Revenue from Contract with Customer | Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk (as a percentage)	100.00%	100.00%	100.00%	100.00%
Revenue from Contract with Customer | Geographic Concentration Risk | United States
Disaggregation of Revenue [Line Items]
Concentration risk (as a percentage)	75.00%	76.00%	79.00%	78.00%
Revenue from Contract with Customer | Geographic Concentration Risk | Other countries
Disaggregation of Revenue [Line Items]
Concentration risk (as a percentage)	25.00%	24.00%	21.00%	22.00%

Revenues - Contract Assets, Con

Revenues - Contract Assets, Contract Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Revenues
Contract assets, net	$ 118,252
Contract liabilities (deferred revenue)	300,724	$ 275,181
Revenue recognized in the period from:
Amounts included in contract liabilities at the beginning of the period	$ 111,375

Revenues - Schedule Of Contract

Revenues - Schedule Of Contract Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Current	$ 186,909	$ 163,959
Long-Term	113,815	111,222
Total	300,724	275,181
TASER
Disaggregation of Revenue [Line Items]
Current	36,075	28,945
Long-Term	31,890	32,811
Total	67,965	61,756
Software and Sensors
Disaggregation of Revenue [Line Items]
Current	150,834	135,014
Long-Term	81,925	78,411
Total	232,759	213,425
Warranty
Disaggregation of Revenue [Line Items]
Current	27,073	25,561
Long-Term	22,430	21,978
Total	49,503	47,539
Warranty | TASER
Disaggregation of Revenue [Line Items]
Current	12,467	11,635
Long-Term	16,937	16,953
Total	29,404	28,588
Warranty | Software and Sensors
Disaggregation of Revenue [Line Items]
Current	14,606	13,926
Long-Term	5,493	5,025
Total	20,099	18,951
Hardware
Disaggregation of Revenue [Line Items]
Current	52,441	41,495
Long-Term	61,579	65,285
Total	114,020	106,780
Hardware | TASER
Disaggregation of Revenue [Line Items]
Current	22,408	16,314
Long-Term	11,498	14,304
Total	33,906	30,618
Hardware | Software and Sensors
Disaggregation of Revenue [Line Items]
Current	30,033	25,181
Long-Term	50,081	50,981
Total	80,114	76,162
Software and Sensors
Disaggregation of Revenue [Line Items]
Current	107,395	96,903
Long-Term	29,806	23,959
Total	137,201	120,862
Software and Sensors | TASER
Disaggregation of Revenue [Line Items]
Current	1,200	996
Long-Term	3,455	1,554
Total	4,655	2,550
Software and Sensors | Software and Sensors
Disaggregation of Revenue [Line Items]
Current	106,195	95,907
Long-Term	26,351	22,405
Total	$ 132,546	$ 118,312

Revenues - Revenue Performance

Revenues - Revenue Performance Obligations (Details) $ in Millions	Jun. 30, 2021USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation	$ 2,040
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01 | Minimum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation to be recognized in the next twelve months (as a percentage)	20.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01 | Maximum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation to be recognized in the next twelve months (as a percentage)	25.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-07-01 | Minimum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	5 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-07-01 | Maximum
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	7 years

Cash, Cash Equivalents, and Inv

Cash, Cash Equivalents, and Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	$ 704,117	$ 652,816
Gross Unrealized Gains	195	401
Gross Unrealized Losses	(60)	(128)
Fair Value	704,252	653,089
Cash and Cash Equivalents	266,379	155,443
Short-Term Investments	389,050	406,667
Long-Term Investments	48,688	90,706
Expected credit loss reserve	(200)	(200)
Cash and cash equivalents	266,372	155,440	$ 319,253
Short-term investments	388,895	406,525
Long-term investments	48,669	90,681
Fair Value, Inputs, Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	218,516	183,789
Gross Unrealized Gains	76	128
Gross Unrealized Losses	(1)
Fair Value	218,591	183,917
Cash and Cash Equivalents	66,152	23,611
Short-Term Investments	144,364	120,178
Long-Term Investments	8,000	40,000
Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	286,175	352,920
Gross Unrealized Gains	119	273
Gross Unrealized Losses	(59)	(128)
Fair Value	286,235	353,065
Cash and Cash Equivalents	801	15,725
Short-Term Investments	244,686	286,489
Long-Term Investments	40,688	50,706
Cash and Cash Equivalents
Restricted Cash and Cash Equivalents Items [Line Items]
Expected credit loss reserve	(7)	(3)
Short-Term Investments
Restricted Cash and Cash Equivalents Items [Line Items]
Expected credit loss reserve	(155)	(142)
Long-Term Investments
Restricted Cash and Cash Equivalents Items [Line Items]
Expected credit loss reserve	(19)	(25)
Cash
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	199,426	116,107
Fair Value	199,426	116,107
Cash and Cash Equivalents	199,426	116,107
Money market funds | Fair Value, Inputs, Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	48,052	23,611
Fair Value	48,052	23,611
Cash and Cash Equivalents	48,052	23,611
Agency bonds | Fair Value, Inputs, Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	73,669	63,794
Gross Unrealized Gains	74	122
Fair Value	73,743	63,916
Cash and Cash Equivalents	5,500
Short-Term Investments	60,169	23,794
Long-Term Investments	8,000	40,000
Treasury bills | Fair Value, Inputs, Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	96,795	96,384
Gross Unrealized Gains	2	6
Gross Unrealized Losses	(1)
Fair Value	96,796	96,390
Cash and Cash Equivalents	12,600
Short-Term Investments	84,195	96,384
State and municipal obligations | Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	101,610	77,130
Gross Unrealized Gains	14	25
Gross Unrealized Losses	(27)	(28)
Fair Value	101,597	77,127
Cash and Cash Equivalents	801
Short-Term Investments	87,596	66,519
Long-Term Investments	13,213	10,611
Certificates of deposit | Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	500	500
Fair Value	500	500
Short-Term Investments	500	500
Corporate bonds | Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	150,082	212,825
Gross Unrealized Gains	105	232
Gross Unrealized Losses	(32)	(100)
Fair Value	150,155	212,957
Cash and Cash Equivalents		2,525
Short-Term Investments	122,607	170,205
Long-Term Investments	27,475	40,095
U.S. Treasury repurchase agreements | Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost		13,200
Fair Value		13,200
Cash and Cash Equivalents		13,200
Treasury inflation - protected securities | Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost		3,291
Gross Unrealized Gains		16
Fair Value		3,307
Short-Term Investments		3,291
Commercial paper | Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	33,983	45,974
Fair Value	33,983	45,974
Short-Term Investments	$ 33,983	$ 45,974

Expected Credit Losses (Details

Expected Credit Losses (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance, beginning of period	$ 3,376
Provision for expected credit losses	126
Amounts written off charged against the allowance	(54)
Other, including foreign currency translation	69
Balance, end of period	3,517
United States
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance, beginning of period	2,902
Provision for expected credit losses	256
Amounts written off charged against the allowance	(54)
Other, including foreign currency translation	78
Balance, end of period	3,182
Other countries
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance, beginning of period	474
Provision for expected credit losses	(130)
Other, including foreign currency translation	(9)
Balance, end of period	335
COVID-19
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Additional reserve for credit loss	$ 1,000

Expected Credit Losses - Type O

Expected Credit Losses - Type Of Customer Receivable (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Expected Credit Losses
Accounts receivable and notes receivable, current	$ 1,973	$ 2,105
Contract assets, net	1,186	794
Long-term notes receivable, net of current portion	358	477
Total allowance for expected credit losses on customer receivables	$ 3,517	$ 3,376

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 35,935	$ 39,194
Finished goods	55,804	50,764
Total inventory	$ 91,739	$ 89,958

Strategic Investments (Details)

Strategic Investments (Details) - USD ($) $ in Thousands	6 Months Ended	16 Months Ended
	Jun. 30, 2021	Jun. 30, 2021
Equity Securities without Readily Determinable Fair Value [Line Items]
Balance, beginning of period	$ 11,711
Investments	20,500	$ 30,156
Observable price changes	40,855	42,910
Sales	(14,546)	(14,546)
Balance, end of period	58,520	58,520
Realized gain on sale of investment	12,300
Strategic investments
Equity Securities without Readily Determinable Fair Value [Line Items]
Balance, beginning of period	9,500
Investments	20,500	27,568
Observable price changes	40,321	42,753
Sales	(14,546)	(14,546)
Balance, end of period	55,775	55,775
Warrants for strategic investment
Equity Securities without Readily Determinable Fair Value [Line Items]
Balance, beginning of period	2,211
Investments		2,588
Observable price changes	534	157
Balance, end of period	$ 2,745	$ 2,745

Other Long-Term Assets (Details

Other Long-Term Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Cash surrender value of corporate-owned life insurance policies	$ 5,055	$ 4,654
Deferred commissions	36,489	32,455
Restricted cash	60	62
Operating lease assets	26,885	22,308
Prepaid expenses, deposits and other	15,755	8,727
Total other long-term assets	$ 84,244	$ 68,206

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued salaries, benefits and bonus	$ 39,487	$ 36,892
Accrued professional, consulting and lobbying fees	1,201	3,055
Accrued warranty expense	901	769	$ 1,012	$ 1,476
Accrued income and other taxes	3,780	3,848
Accrued inventory in transit	10,979	4,597
Other accrued expenses	10,560	10,682
Accrued liabilities	$ 66,908	$ 59,843

Income Taxes (Details)

Income Taxes (Details) $ in Millions	6 Months Ended
	Jun. 30, 2021USD ($)
Tax Credit Carryforward [Line Items]
Deferred tax assets, net	$ 51.9
Liability for unrecognized tax benefits	7.6
Research and development tax credit studies	$ 3.3
Effective tax rate (as a percentage)	6.40%
Effective tax rate, before discrete period adjustment (as a percentage)	(19.10%)
Restricted Stock Units (RSUs)
Tax Credit Carryforward [Line Items]
Discrete tax benefit, stock-based compensation	$ 25.7
State Tax
Tax Credit Carryforward [Line Items]
Unrecognized tax benefits recognized during period	$ 7.6

Stockholders' Equity - CEO Perf

Stockholders' Equity - CEO Performance Award - Additional Information (Details) $ in Thousands	May 24, 2018USD ($)itemtrancheshares	Jun. 30, 2021USD ($)shares	Jun. 30, 2021USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market capitalization goal for such tranche	$ 2,500,000
Market capitalization goal increment	$ 1,000,000
Recorded share-based compensation expense			$ 204,200
Number of options expected to vest | shares		4,800,000	4,800,000
Revenue goal number 1		$ 710,058	$ 710,058
Adjusted EBITDA goal number 9		125,000	125,000
Revenue goal number 2		860,058	860,058
Adjusted EBITDA goal number 10		155,000	155,000
Revenue goal number 3		1,010,058	1,010,058
Adjusted EBITDA goal number 11		175,000	175,000
Revenue goal number 4		1,210,058	1,210,058
Adjusted EBITDA goal number 12		190,000	190,000
Revenue goal number 5		1,410,058	1,410,058
Adjusted EBITDA goal number 13		200,000	200,000
Revenue goal number 6		1,610,058	1,610,058
Adjusted EBITDA goal number 14		210,000	210,000
Revenue goal number 7		1,810,058	1,810,058
Adjusted EBITDA goal number 15		220,000	220,000
Revenue goal number 8		2,010,058	2,010,058
Adjusted EBITDA goal number 16		230,000	230,000
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares authorized (in shares) | shares	6,365,856
Updated estimates, stock-based compensation expense		107,300	$ 158,700
Number of options vested | shares			1,600,000
Weighted average period over which costs are recognized			1 year 6 months 25 days
CEO Performance Award
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized share-based compensation cost related to unvested stock option awards, probable of achievement		$ 41,700	$ 41,700
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of vesting tranches of share-based awards | tranche	12
Vesting period	10 years
Number of performance goals, revenue | item	8
Number of performance goals, adjusted EBITDA | item	8

Stockholders' Equity - eXponent

Stockholders' Equity - eXponential Stock Performance Plan (Details) $ in Millions	Feb. 12, 2019USD ($)itemtranche	May 24, 2018USD ($)shares	Jun. 30, 2021USD ($)shares	Jun. 30, 2021USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market capitalization goal for such tranche		$ 2,500
Market capitalization goal increment		$ 1,000
Recorded share-based compensation expense				$ 204.2
Number of options expected to vest | shares			4,800,000	4,800,000
eXponential Stock Units | 2019 eXponential Stock Performance Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares authorized (in shares) | shares			23,000	23,000
Expiration period	9 years
Number of vesting tranches of share-based awards | tranche	12
Market capitalization goal for such tranche	$ 2,500
Number of performance goals, revenue | item	8
Number of performance goals, adjusted EBITDA | item	8
Market capitalization goal increment	$ 1,000
Anti-dilution provision, maximum shares growth rate per year				3.00%
Recorded share-based compensation expense				$ 151.4
Unrecognized stock-based compensation expense			$ 42.3	$ 42.3
Weighted average period over which costs are recognized				2 years 2 months 12 days
eXponential Stock Units | 2019 eXponential Stock Performance Plan | Eleven Operational Goals
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options expected to vest | shares			4,000,000	4,000,000
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares authorized (in shares) | shares		6,365,856
Weighted average period over which costs are recognized				1 year 6 months 25 days

Stockholders' Equity - Summary

Stockholders' Equity - Summary of RSU and PSU Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Number of Units outstanding, beginning of year (in shares) | shares	1,107
Number of Units, Granted (in shares) | shares	98
Number of Units, Released (in shares) | shares	(276)
Number of Units, Forfeited (in shares) | shares	(64)
Number of Units outstanding, end of period (in shares) | shares	865
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value, Units outstanding, beginning of year (in dollars per share) | $ / shares	$ 76.10
Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares	149.92
Weighted Average Grant Date Fair Value, Released (in dollars per share) | $ / shares	51.65
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares	98.43
Weighted Average Grant Date Fair Value, Units outstanding, end of period (in dollars per share) | $ / shares	$ 90.59
Aggregate intrinsic value at end of period | $	$ 152,892
Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Number of Units outstanding, beginning of year (in shares) | shares	5,618
Number of Units, Granted (in shares) | shares	225
Number of Units, Released (in shares) | shares	(1,696)
Number of Units, Forfeited (in shares) | shares	(60)
Number of Units outstanding, end of period (in shares) | shares	4,087
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value, Units outstanding, beginning of year (in dollars per share) | $ / shares	$ 35.71
Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares	50
Weighted Average Grant Date Fair Value, Released (in dollars per share) | $ / shares	41.20
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares	35.80
Weighted Average Grant Date Fair Value, Units outstanding, end of period (in dollars per share) | $ / shares	$ 34.22
Aggregate intrinsic value at end of period | $	$ 722,593

Stockholders' Equity - RSU and

Stockholders' Equity - RSU and PSU - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	May 17, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Recorded share-based compensation expense			$ 204,200
Tax payments, for net share settlement of share based award			$ 10,312	$ 5,767
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value price per share (in dollars per share)		$ 176.80	$ 176.80
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value price per share (in dollars per share)		$ 176.80	$ 176.80
Unrecognized stock-based compensation expense		$ 57,400	$ 57,400
Weighted average period over which costs are recognized			2 years 1 month 6 days
Number of shares vested			276
Number of units outstanding (in shares)		865	865		1,107
Shares withheld, for net share settlement of share based award (in shares)			46
Tax payments, for net share settlement of share based award			$ 7,500
Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value price per share (in dollars per share)		$ 176.80	$ 176.80
Unrecognized stock-based compensation expense		$ 44,800	$ 44,800
Weighted average period over which costs are recognized			2 years 2 months 19 days
Performance criteria had been met (in shares)			2,200
Number of shares vested			1,696
Number of units outstanding (in shares)		4,087	4,087		5,618
Shares withheld, for net share settlement of share based award (in shares)			19
Tax payments, for net share settlement of share based award			$ 2,800
eXponential Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting	4.00%
Modification, number of shares vested	36
Modification, stock-based compensation expense		$ 500	$ 900
Minimum | eXponential Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Minimum holding period			2 years 6 months

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of the Company's Stock Options Activity (Details) - Stock Options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options, Options outstanding, beginning of year (in shares)	6,366
Number of options, Exercised (in shares)	0
Number of options, Options outstanding, end of year (in shares)	6,366
Number of options, Options exercisable, end of period (in shares)	4,243
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price, Options outstanding, beginning of year (in dollars per share)	$ 28.58
Weighted average exercise price, Options outstanding, end of period (in dollars per share)	28.58
Weighted average exercise price, Options exercisable, end of period (in dollars per share)	$ 28.58
Weighted average remaining contractual life, Options outstanding, end of period	6 years 7 months 28 days
Weighted average remaining contractual life, Options exercisable, end of period	6 years 7 months 28 days
Aggregate intrinsic value, Options outstanding, end of period	$ 943,547
Aggregate intrinsic value, Options exercisable, end of period	$ 629,031

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value price per share (in dollars per share)	$ 176.80
Number of options, Exercised (in shares)	0
Total intrinsic value of options exercised	$ 5.1
Number of options outstanding (in shares)	6,366	6,366
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)	2,100

Stockholders' Equity - Reported

Stockholders' Equity - Reported Share-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 137,549	$ 33,835	$ 227,159	$ 54,030
Cost of products sold and services delivered
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,838	836	3,327	1,426
Sales, general and administrative expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	114,089	26,766	185,104	41,736
Research and development expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 21,622	$ 6,233	$ 38,728	$ 10,868

Stockholders' Equity - Stock Re

Stockholders' Equity - Stock Repurchase Plan - Additional Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Feb. 28, 2019	Feb. 29, 2016
2019 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance (in shares)			6,000,000
Shares available for grant under the plan (in shares)	1,800,000
2016 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding common stock repurchase program authorized amount (up to)				$ 50,000,000
Shares repurchased during period (in shares)	0	0
Remaining authorized repurchase amount	$ 16,300,000

Line of Credit (Details)

Line of Credit (Details)	6 Months Ended
	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Maximum ratio of total liabilities to tangible net worth	2.50
Line of Credit
Debt Instrument [Line Items]
Accordion feature allowing for increase in borrowing capacity	$ 100,000,000
Letters of credit outstanding amount	6,100,000
Available borrowing under letter of credit	43,900,000
Line of credit borrowings	$ 0	$ 0
EBITDA ratio	0
Line of Credit | Unsecured Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Total availability under line of credit agreement	$ 50,000,000
Line of Credit | Letter of Credit
Debt Instrument [Line Items]
Available borrowing under letter of credit	$ 20,000,000
Minimum | Line of Credit | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument basis spread on variable rate (as a percentage)	1.00%
Maximum | Line of Credit | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument basis spread on variable rate (as a percentage)	1.50%

Commitments and Contingencies (

Commitments and Contingencies (Details)	Jun. 30, 2021USD ($)lawsuit	Apr. 08, 2021USD ($)$ / sharesshares
Loss Contingencies [Line Items]
Number of lawsuits against Company | lawsuit	4
Self insurance on product claim	$ 5,000,000
Share Purchase Agreement with Cellebrite DI Ltd.
Loss Contingencies [Line Items]
Number of shares of common stock expected to be purchased | shares		9,000,000
Share price | $ / shares		$ 10
Expected investment amount		$ 90,000,000
Line of Credit
Loss Contingencies [Line Items]
Letters of credit outstanding amount	6,100,000
Outstanding letters of credit and bank guarantees not drawn against credit facility	2,000,000
Surety Bond
Loss Contingencies [Line Items]
Bonds outstanding	21,500,000
Expire In March 2022 and May 2022 | Surety Bond
Loss Contingencies [Line Items]
Letters of credit outstanding amount	6,100,000
Expiring in 2021 | Surety Bond
Loss Contingencies [Line Items]
Bonds outstanding	400,000
Expiring in 2022 | Surety Bond
Loss Contingencies [Line Items]
Bonds outstanding	3,100,000
Expiring in 2023 | Surety Bond
Loss Contingencies [Line Items]
Bonds outstanding	7,500,000
Expiring in 2024 | Surety Bond
Loss Contingencies [Line Items]
Bonds outstanding	$ 10,500,000

Employee Benefit Plans (Details

Employee Benefit Plans (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Defined Benefit Plan Disclosure [Line Items]
Employee deferrals deemed vested upon contribution (as a percentage)			100.00%
Defined contribution plan, cost	$ 1.8	$ 1.3	$ 3.8	$ 2.8
Maximum
Defined Benefit Plan Disclosure [Line Items]
Deferral percentage of base salary (as a percentage)			80.00%
Deferral percentage of other compensation (as a percentage)			100.00%

Segment Data (Details)

Segment Data (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)segment	Jun. 30, 2020USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments of company | segment			2
Net sales	$ 218,795	$ 141,259	$ 413,814	$ 288,421
Cost of sales	80,866	53,082	152,532	111,636
Gross margin	137,929	88,177	261,282	176,785
Research and development	53,952	29,560	100,970	55,941
TASER
Segment Reporting Information [Line Items]
Net sales	112,528	70,490	211,527	146,385
Cost of sales	37,846	27,242	70,791	57,490
Gross margin	74,682	43,248	140,736	88,895
Research and development	12,313	3,762	21,556	6,794
Software and Sensors
Segment Reporting Information [Line Items]
Net sales	106,267	70,769	202,287	142,036
Cost of sales	43,020	25,840	81,741	54,146
Gross margin	63,247	44,929	120,546	87,890
Research and development	41,639	25,798	79,414	49,147
Product
Segment Reporting Information [Line Items]
Net sales	156,427	98,755	297,313	206,043
Cost of sales	65,301	43,825	123,917	92,709
Product | TASER
Segment Reporting Information [Line Items]
Net sales	110,637	69,877	207,939	145,052
Cost of sales	37,701	27,242	70,646	57,490
Product | Software and Sensors
Segment Reporting Information [Line Items]
Net sales	45,790	28,878	89,374	60,991
Cost of sales	27,600	16,583	53,271	35,219
Service
Segment Reporting Information [Line Items]
Net sales	62,368	42,504	116,501	82,378
Cost of sales	15,565	9,257	28,615	18,927
Service | TASER
Segment Reporting Information [Line Items]
Net sales	1,891	613	3,588	1,333
Cost of sales	145	0	145	0
Service | Software and Sensors
Segment Reporting Information [Line Items]
Net sales	60,477	41,891	112,913	81,045
Cost of sales	$ 15,420	$ 9,257	$ 28,470	$ 18,927